

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

October 22, 1998

Deputy Assistant Commissioner for Patents

Washington, D.C. 20231

PATENT APPLICATION

:

Transmitted herewith for filing are the specification and claims of the patent application of:

John Loike and Samuel C. Silverstein

for

Inventor(s)

A Method of Preventing and Treating Bacterial Infection of Sutures and Prosthetic Devices, and Promoting Ingress of Leukocytes into Tumor Foci

Title of Invention

Also enclosed are:

☒ 19 sheet(s) of ☐ informal ☒ formal drawings.

☐ Oath or declaration of Applicant(s).

☐ A power of attorney

☐ An assignment of the invention to _____

☒ A Preliminary Amendment

☐ A verified statement to establish small entity status under 37 C.F.R. §1.9 and §1.27.

The filing fee is calculated as follows:

CLAIMS AS FILED, LESS ANY CLAIMS CANCELLED BY AMENDMENT

	NUMBER FILED		NUMBER EXTRA*		RATE		FEE	
					SMALL ENTITY	OTHER ENTITY	SMALL ENTITY	OTHER ENTITY
Total Claims	54-20	=	34	X	\$11.00	\$22.00	= \$	\$ 748.00
Independent Claims	4-3	=	1	X	\$41.00	\$82.00	= \$	\$ 82.00
Multiple Dependent Claims Presented: <input type="checkbox"/> Yes <input checked="" type="checkbox"/> No					\$135.00	\$270.00	= \$	\$ -0-
*If the different in Col. 1 is less than zero, enter "0" in Col. 2					BASIC FEE		\$ 395	\$ 790
					TOTAL FEE		\$	\$1,620.00

John Loike and Samuel C. Silverstein
U.S. Serial No.: Not Yet Known
International Filing Date: 22 April 1997

Letter of Transmittal
Page 2

X A check in the amount of \$ 1,620.00 to cover the filing fee.

 Please charge Deposit Account No. in the amount of \$.

X The Commissioner is hereby authorized to charge any additional fees which may be required in connection with the following or credit any over-payment to Account No. 03-3125:

X Filing fees under 37 C.F.R. §1.16.

X Patent application processing fees under 37 C.F.R. §1.17.

 The issue fee set in 37 C.F.R. §1.18 at or before mailing of the Notice of Allowance, pursuant to 37 C.F.R. §1.311(b).

X Three copies of this sheet are enclosed.

 A certified copy of previously filed foreign application No. filed in on .
Applicant(s) hereby claim priority based upon this aforementioned foreign application under 35 U.S.C. §119.

X Other (identify) Express Mail Certificate of Mailing bearing Label No. EM525892713US, dated October 22, 1998, and a Statement of Compliance under 37 C.F.R. §1.821(f), with a diskette containing a computer-readable form of sequence listing.

Respectfully submitted,



John P. White
Registration No. 28,678
Attorney for Applicants
Cooper & Dunham LLP
1185 Avenue of the Americas
New York, New York 10036
(212) 278-0400

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicants : John Loike and Samuel C. Silverstein

Serial No. : Not Yet Known

Int'nat'l.

Filing Date: 22 April 1997

For : A METHOD OF PREVENTING AND TREATING BACTERIAL
INFECTION OF SUTURES AND PROSTHETIC DEVICES, AND
PROMOTING INGRESS OF LEUKOCYTES INTO TUMOR FOCI

1185 Avenue of the Americas
New York, New York 10036
October 22, 1998

Assistant Commissioner of Patents
Washington, D.C. 20231
Box Patent Application

Sir:

PRELIMINARY AMENDMENT TO THE ACCOMPANYING CONTINUATION
APPLICATION FILED UNDER 37 C.F.R. §1.53

Applicant requests that the following amendments be made in the
above-identified application:

In the Title:

On pages 1 and 68 please delete the present title and insert the
following new title:

--A METHOD OF TREATING INFECTION OF SUTURES AND PROSTHETIC
DEVICES--

In the Specification:

On page 1 delete lines 7-9 and insert the following:


--This application is a continuation of PCT International
Application No. PCT/US97/06577, filed April 22, 1997, which
is a continuation-in-part application of U.S. Serial No.
08/635,572, filed April 22, 1996, the contents of which are
hereby incorporated by reference into the present
application.--

John Loike and Samuel C. Silverstein
Serial No.: Not Yet Known
International Filing Date: 22 April 1997
Page 2

If a telephone interview would be of assistance in advancing prosecution of the subject application, applicants' undersigned attorney invites the Examiner to telephone at the number provided below.

No fee, other than the enclosed \$1,620.00 filing fee, is deemed necessary in connection with the filing of this Preliminary Amendment. However, if any other fee is required, authorization is hereby given to charge the amount of such fee to Deposit Account No. 03-3125.

Respectfully submitted,



John P. White
Registration No. 28,678
Attorney for Applicants
Cooper & Dunham LLP
1185 Avenue of the Americas
New York, New York 10036
(212) 278-0400

004744 1033
"CHARTER"

Application
for
United States Letters Patent

To all whom it may concern:

Be it known that

John Loike and Samuel C. Silverstein
have invented certain new and useful improvements in

A METHOD OF PREVENTING AND TREATING BACTERIAL INFECTION OF SUTURES AND PROSTHETIC
DEVICES, AND PROMOTING INGRESS OF LEUKOCYTES INTO TUMOR FOCI

of which the following is a full, clear and exact description.

**A METHOD OF PREVENTING AND TREATING BACTERIAL INFECTION
OF SUTURES AND PROSTHETIC DEVICES, AND PROMOTING
INGRESS OF LEUKOCYTES INTO TUMOR FOCI**

This application is a continuation-in-part application of U.S. Serial No. 08/635,572, filed on April 22, 1996, which is hereby incorporated by reference.

The invention disclosed herein was made with Government support under NIH Grant No. AI 20516 from the Department of Health and Human Services. Accordingly, the U.S. Government has certain rights in this invention.

Throughout this application, various references are referred to within parentheses. Disclosures of these publications in their entirety are hereby incorporated by reference into this application to more fully describe the state of the art to which this invention pertains. Full bibliographic citation for these references may be found at the end of this application, preceding the sequence listing and the claims.

Background of the Invention

Soluble or cell bound chemoattractants (1,2), stimulate polymorphonuclear leukocytes (PMN) to emigrate from the vasculature and migrate toward sites of injury, infection, and inflammation. PMNs express unique plasma membrane receptors for many different chemoattractants and cytokines [e.g., IL-8, leukotriene B₄ (LTB₄), formyl-methionyl-leucyl-phenylalanine (fMLP) and TNF- α] (3). Interactions between these receptors and soluble or surface-bound chemoattractants or cytokines signal PMNs to alter their expression and/or activity of selectins and integrins (4,5), and regulate PMN spatial orientation and movements. (6).

Tenascin, also referred to as cytotactin, hexabrachion,

and glioma-mesenchymal extracellular matrix protein (41,43,44), forms a disulfide linked multimeric six-armed structure called a hexabrachion (43). Tenascin is expressed in many tissues during embryonic development, and is thought to play an important role in the development of muscles and tendons, mammary glands, hair follicles, teeth, kidney, bone and cartilage (43,50,51). In adults, tenascin is expressed in T-cell dependent regions of lymphoid tissues (40), in areas of cellular injury, and in malignant, but not benign tumors (41,43). In areas of injury, tenascin is present in granulation tissue (41,55), in association with proliferating and migrating epidermal cells (42,49), and in arteries whose endothelial cells have been damaged (57). In malignant neoplasms, tenascin is produced by the tumor cells (63) and deposited in the stroma of gliomas, mammary carcinomas, colon cancers, Wilm's tumor, basal cell carcinomas, melanomas, and squamous cell carcinomas (41,64).

There is little information regarding the physiological or patho-physiological role(s) of tenascin at sites of tissue injury, malignancy or atherosclerotic lesions. In extracellular matrices, tenascin promotes the adhesion of endothelial cells and bone marrow cells (38,48). Tenascin also blocks the attachment of several other cell types to fibronectin-coated surfaces in vitro (47,52), and the migration of neural crest cells (20,43,62).

Summary of the Invention

5 The present invention provides a method of treating an infection caused by bacterial cells located on a surface of a foreign body over and around which fibrin has been deposited, the foreign body being present in a subject, which comprises administering to the subject an agent capable of inhibiting signalling mediated by a β_1 integrin cell surface receptor of leukocyte cells in an amount effective to enhance the migration of leukocyte cells into or through the fibrin so as to permit the leukocyte cells to reach and kill the bacterial cells and thereby treat the infection.

15 The present invention also provides a method of preventing a chronic infection from occurring due to the presence of bacterial cells on a surface of a foreign body in a subject, which comprises coating the foreign body before placing it in the subject with a fibrinolytic agent capable of preventing the accumulation of fibrin on the surface of the foreign body so as to permit leukocyte cells to reach and kill any bacterial cells present on the surface of the foreign body and thereby prevent the chronic infection.

25 The present invention further provides a method of treating a malignant tumor comprising of malignant tumor cells over and around which tenascin has been deposited, the malignant tumor being present in a subject, which comprises administering to the subject an agent capable of inhibiting signalling mediated by a β_1 integrin cell surface receptor of leukocyte cells in an amount effective to enhance the migration of leukocyte cells through the tenascin so as to permit the leukocyte cells to reach and kill the malignant tumor cells and thereby treat the malignant tumor.

The present invention also provides a method of treating a chronic inflammation in a subject caused by an increase in the number of leukocyte cells present at the site of the chronic inflammation which comprises administering to
5 the subject an agent capable of stimulating signalling mediated by a β_1 integrin cell surface receptor of leukocyte cells in an amount effective to inhibit the migration of leukocyte cells toward the site of the chronic inflammation so as to reduce the number of
10 leukocyte cells present at the site and thereby treat the chronic inflammation.

200007-494760

Brief Description of the Figures

Figures 1A and 1B show that IL-8 and LTB4 promote PMN migration through fibrin gels and plasma clots. Fibrin gels (A) or plasma clots (B) were formed on top of filters with 8 μ m pores in tissue culture inserts as described under Materials and Methods. 10^6 PMNs were added to the upper chamber and the indicated chemoattractants or cytokines were added to either the lower or upper chamber as indicated. The preparation then was incubated at 37°C for 6 hrs, at which time the number of cells in the lower chamber was determined using a Coulter counter. Concentrations of chemoattractants/cytokines used were: 0.75×10^{-7} M for IL-8, 1.0×10^{-7} M for LTB4, 0.5×10^{-7} M for TNF and 1.0×10^{-7} M for fMLP. Fewer than 1500 PMNs migrated through fibrin gels in the absence of any stimulator.

Figures 2A and 2B show PMN migration through fibrin gels in response to varying concentrations of chemoattractants [fMLP, TNF (A); LTB4, IL-8 (B)]. Fibrin gels were formed on filters of cell culture inserts as described in Experimental Procedures and chemoattractants or cytokines at the indicated concentrations were added to the lower chamber. 10^6 PMNs were added to the upper chamber and the preparation was incubated at 37°C for 6 hrs, at which time the number of cells in the lower chamber was counted as described in Figures 1A and 1B.

Figures 3A and 3B show that an IL-8 or LTB4 gradient is required for PMN migration through fibrin gels. Fibrin gels were formed in cell culture inserts as described in Experimental Procedures. IL-8 (A) or LTB4 (B) were added to the lower compartment at a fixed concentration and to the upper compartment at varying concentrations as indicated. 10^6 PMNs were added to the upper chamber and the preparation was incubated at 37°C for 6 hrs, at which

time the number of cells in the lower chamber was counted as described in Figures 1A and 1B.

5 Figure 4 shows a time course of PMN migration through
fibrin gels. Fibrin gels were formed in cell culture
inserts as described under Experimental Procedures. IL-8
(0.75×10^{-7} M) or LTB₄ (10^{-7} M) were added to the lower
chamber. The number of PMNs that migrated through a
10 fibrin gel was determined at the indicated times as
described in Figure 1A and 1B.

15 Figures 5A, 5B, 5C, 5D, 5E, and 5F show a confocal
microscopic analysis of PMN migration through fibrin
gels. Fibrin gels were formed as described under
Experimental Procedures and chemoattractants or cytokines
at the indicated concentrations were added to the lower
chamber. 10^6 PMNs, prelabeled with calcein as described
under Experimental Procedures, were added to the upper
chamber at 37°C. At the indicated times, the filters
20 were removed from the inserts, washed and viewed by
confocal microscopy as described under Experimental
Procedures. All samples were viewed en-face, the images
were rotated 90°C. The surface of the gel is marked with
a bar. (A and B), fMLP (10^{-7} M); (C and D), TNF (0.5×10^{-7}
25 7 M); (E and F), IL-8 (0.75×10^{-7} M).

Figure 6 shows that degradation of 125 I-fibrin by PMNs
does not account for the increased of IL-8 of LTB₄
stimulated PMNs. Cell culture inserts containing 125 I-
30 labeled fibrin gels were prepared as described. 10^6 PMNs
were added to the insert and the indicated
chemoattractants/cytokine were added to the lower
compartment as described in Figures 1A and 1B. The
concentrations of chemoattractants used are the same as
35 described in Figures 5A, 5B, 5C, 5D, 5E, and 5F. After
a 6 hr incubation at 37°, media from both the upper and
lower compartments were collected and the assayed for the

amount of radioactivity in TCA-soluble and insoluble fractions as described in Materials and Methods. This figure is representative of experiments repeated three times with similar results. The data in this figure are the average of values from duplicate samples.

Figures 7A and 7B show PMN migration through filters coated with different types of matrix proteins. PMN migration through filters coated with gels formed with reconstituted basement membrane (Matrigel), or collagen IV (A), or with filters coated with fibrinogen, or fibronectin (B), was measured in response to TNF (5×10^{-7} M), fMLP (10^{-7} M), IL-8 (0.75×10^{-8} M) or LTB4 (10^{-8} M). Migration was essentially complete within 2 hr. The last column of Figure 5A reports migration of TNF-stimulated PMN through a collagen IV gel impregnated with fibrin.

Figure 8 shows "Closeness" of PMN apposition to fibrin matrices. PMNs stimulated with the indicated chemoattractants were allowed to adhere for 15 min to glass surfaces coated with fibrin as described under Experimental Procedures. PMNs forming close zones of adhesion are defined as those that exclude the entry of Rh-PEG into the area of adhesion between the cell and the underlying matrix as assayed by fluorescence microscopy. The concentrations of chemoattractants/cytokines used were the same as in Fig. 6. Less than 20% of unstimulated PMNs that adhered to the fibrin formed close zones of apposition.

Figures 9A and 9B show the effect of combinations of chemoattractants/cytokines in promoting PMN migration through fibrin gels. PMN migration through fibrin gels was measured in response to TNF (A) or fMLP (B) added in combination to the bottom compartment, at the concentrations indicated. The concentrations of IL-8 and LTB4 used were the same as in Figures 5A, 5B, 5C, 5D, 5E,

and 5F. PMN migration into the lower compartment was measured as described in Figures 1A and 1B after a 6 hr incubation at 37°C.

- 5 Figures 10A and 10B show that fMLP promotes PMN migration through fibrin gels when these cells are treated with antibodies directed against β_1 integrins (A) or incubated in medium containing synthetic peptide (B). Fibrin gels were formed on filters of cell culture inserts as described in Experimental Procedures and fMLP (10^{-7} M) or LTB4 (10^{-7} M) was added to the medium in the lower chamber. Figure 10A - 10^6 PMNs were pre-incubated in medium containing antibodies against rat or human β_1 integrins, or antibodies against the α_5 subunit of human $\alpha_5\beta_1$ integrin, or against the human β_2 integrin complement receptor 3 (CR3), or against the human β_2 integrin p150/95, or against human β_3 integrins for 15 min at 4°C. PMNs were placed in the upper chamber of cell culture inserts in the same medium and the inserts were incubated for 6 hrs at 37°C, at which time the number of cells in the lower chamber was determined using a Coulter Counter. Figure 10B - 10^6 PMNs were placed in medium containing the synthetic peptide GRGDSP (SEQUENCE ID NO. 1) (1mg/ml) or the peptide GRGESD (SEQUENCE ID NO. 2) (1mg/ml). The mixture was added to the upper chamber of cell culture inserts and the inserts were incubated for 6 hrs at 37°C, at which time the number of cells in the lower chamber was counted as in Figure 10A.
- 10
- 15
- 20
- 25
- 30 Figures 11A and 11B show that tenascin inhibits the chemotaxis of mononuclear phagocytes through Matrigel-coated filters. Cell inserts coated with either Matrigel or Matrigel and chick tenascin were prepared as described under Experimental Procedures. 10^6 freshly harvested monocytes (A), or monocytes cultured for 24 h (B), were then added to the upper compartment and the indicated chemoattractant [TNF (5×10^{-7} M), LTB4 (10^{-7} M) or fMLP
- 35

(10^{-7} M)] was added to the lower compartment. The inserts were incubated for 24 h at 37° C and the cells that migrated into the lower compartment were counted using a Coulter Counter.

5

Figure 12 shows that chick tenascin inhibits the chemotaxis of PMNs through Matrigel-coated filters. Cell inserts coated with either Matrigel or Matrigel and chick tenascin were prepared as described under Experimental Procedures. 10^6 freshly isolated PMNs were added to the upper compartment and the indicated chemoattractant [TNF (5×10^{-7} M), LTB4 (10^{-7} M), or fMLP (10^{-7} M)], was added to the lower compartment. The inserts were incubated for 2-4 h at 37° C and the cells that migrated into the lower compartment were counted using a Coulter Counter as in Figures 11A and 11B.

Figures 13A and 13B show that human tenascin inhibits the chemotaxis of monocytes or PMNs through Matrigel coated filters. Cell inserts coated with either Matrigel or Matrigel and human tenascin were prepared as described under Experimental procedures. 5×10^5 freshly isolated monocytes, or 10^6 PMNs were added to the upper compartment and the indicated chemoattractant [fMLP (10^{-7} M) or LTB4 (10^{-7} M)] was added to the lower compartment. Migration of monocytes (A) was allowed to proceed for 24 h at 37° C. Migration of PMNs (B) was allowed to proceed for 6 h at 37° C. and the cells that migrated into the lower compartment were counted using a Coulter Counter as in Figures 11A and 11B.

Figure 14 shows that chick tenascin inhibits the migration of cultured monocytes through Matrigel-coated filters in a dose dependent fashion. Cell inserts were coated with Matrigel and then incubated with PBS containing the indicated concentrations of tenascin. The filters were washed with PBS. 2×10^5 cultured monocytes

were added to the upper compartment. TNF (5×10^{-7} M) was added to the lower compartment and the cells were allowed to migrate for 24 h at 37° C. This experiment is representative of 3 experiments. Fewer than 1500
5 cultured monocytes migrated in the absence of any chemoattractant.

Figure 15 shows binding of radiolabeled tenascin to Matrigel-coated filters. 125 I-labeled chick tenascin was
10 prepared as described under Experimental Procedures and mixed with unlabeled tenascin at a protein ratio of 1:100. This mixture was added to Matrigel-coated inserts in the amounts indicated and the inserts were incubated at 37° C for 4 h, conditions identical to those used for
15 the migration experiments described in Figures 11A and 11B. The filters then were washed, cut from the inserts, and counted in a LKB γ -counter.

Figure 16 shows the effects of tenascin on the migration
20 of cultured monocytes through filters coated with collagen I. Cell inserts were coated with 40μ g of collagen I. PBS containing 5μ g of chick tenascin was added to some of the inserts for 4 h as described under Experimental Procedures. 5×10^5 cultured monocytes were
25 added to the upper compartment of the inserts and allowed to migrate for 24 h in the absence of a chemoattractant or in response to TNF (5×10^{-7} M) or LTB $_4$ (10^{-7} M) in the lower compartment. The cells that migrated into the lower compartment were counted as described in Figure 11A
30 and 11B.

Figures 17A and 17B show that F(ab) $'_2$ fragments of anti-tenascin antibodies or anti- β_1 monoclonal antibodies promote monocyte and PMN chemotaxis through
35 Matrigel/tenascin coated filters. 10^6 freshly isolated monocytes (A) or PMNs (B) were used as described in Figures 11A, 11B and 12. Where indicated the cells were

pre-incubated for 30 min at 4° C with various antibodies [2 µg/ml] before adding them to the upper compartment of the chemotaxis chambers. The antibodies used were anti-tenascin (46), P4C10 (anti-β₂), and LeuM5 (7) (anti-α_xβ₂).

- 5 The cells that migrated into the lower compartment at 24 h (A) and at 4 h (B) were determined as described in Figures 11A and 11B.

Detailed Description of the Invention

5 The present invention provides a method of treating an infection caused by bacterial cells located on a surface of a foreign body over and around which fibrin has been deposited, the foreign body being present in a subject, which comprises administering to the subject an agent capable of inhibiting signalling mediated by a β_1 integrin cell surface receptor of leukocyte cells in an amount effective to enhance the migration of leukocyte cells into or through the fibrin so as to permit the leukocyte cells to reach and kill the bacterial cells and thereby treat the infection.

15 In one embodiment of the invention, the foreign body is a prosthetic device, a catheter, or a suture.

In another embodiment of the invention, the subject is a mammal such as a human.

20 In yet another embodiment of the invention, the leukocyte cells are polymorphonuclear leukocyte cells such as neutrophils, basophils, and eosinophils.

25 In another embodiment of the invention, the leukocyte cells are monocytes or macrophages.

30 In yet another embodiment of the invention, the agent is a peptide such as a peptide containing a β_1 integrin-binding domain, specifically one comprising GRGDSP. The agent can also be a peptidomimetic compound.

35 In another embodiment of the invention, the agent is an antibody or a fragment thereof that specifically binds to the β_1 integrin cell surface receptor of leukocyte cells.

The present invention also provides a method of

091784760

preventing a chronic infection from occurring due to the presence of bacterial cells on a surface of a foreign body in a subject, which comprises coating the foreign body before placing it in the subject with a fibrinolytic agent capable of preventing the accumulation of fibrin on the surface of the foreign body so as to permit leukocyte cells to reach and kill any bacterial cells present on the surface of the foreign body and thereby prevent the chronic infection.

10

In one embodiment of the invention, the foreign body is a prosthetic device, a catheter, or a suture.

15

In another embodiment of the invention, the subject is a mammal such as a human.

20

In yet another embodiment of the invention, the fibrinolytic agent is plasminogen activator such as urokinase, streptokinase, or tissue plasminogen activator.

25

The present invention further provides a method of treating a malignant tumor comprising of malignant tumor cells over and around which tenascin has been deposited, the malignant tumor being present in a subject, which comprises administering to the subject an agent capable of inhibiting signalling mediated by a β_1 integrin cell surface receptor of leukocyte cells in an amount effective to enhance the migration of leukocyte cells through the tenascin so as to permit the leukocyte cells to reach and kill the malignant tumor cells and thereby treat the malignant tumor.

30

In one embodiment of the invention, the subject is a mammal such as human.

35

In another embodiment of the invention, the leukocyte

2025 RELEASE UNDER E.O. 14176

cells are polymorphonuclear leukocyte cells such as neutrophils, basophils, and eosinophils.

5 In yet another embodiment of the invention, the leukocyte cells are monocytes or macrophages.

10 In another embodiment of the invention, the leukocyte cells are lymphocyte cells such as NK cells and killer cells.

15 In yet another embodiment of the invention, the agent is a peptide such as a peptide containing a β_1 integrin-binding domain, specifically one comprising GRGDSP. The agent can also be a peptidomimetic compound.

20 In another embodiment of the invention, the agent is an antibody or a fragment thereof that specifically binds to the β_1 integrin cell surface receptor of leukocyte cells.

25 The present invention also provides a method of treating a chronic inflammation in a subject caused by an increase in the number of leukocyte cells present at the site of the chronic inflammation which comprises administering to the subject an agent capable of stimulating signalling mediated by a β_1 integrin cell surface receptor of leukocyte cells in an amount effective to inhibit the migration of leukocyte cells toward the site of the chronic inflammation so as to reduce the number of leukocyte cells present at the site and thereby treat the
30 chronic inflammation.

In one embodiment of the invention, the subject is a mammal such as human.

35 In another embodiment of the invention, the leukocyte cells are polymorphonuclear leukocyte cells such as neutrophils, basophils, and eosinophils.

In yet another embodiment of the invention, the leukocyte cells are monocytes or macrophages.

5 In yet another embodiment of the invention, the agent is a peptide such as a peptide containing a β_2 integrin-binding domain, specifically one comprising GRGDSP. The agent can also be a peptidomimetic compound.

10 This invention will be better understood from the Experimental Details which follow. However, one skilled in the art will readily appreciate that the specific methods and results discussed are merely illustrative of the invention as described more fully in the claims which follow thereafter.

15

Experimental Details

Example 1

20 The evolution of many chemically distinct chemoattractants and receptors suggests that in addition to promoting adhesion and directing PMN locomotion these molecules might regulate the strength of PMN adhesion to specific matrix proteins. The findings that TNF
25 stimulates PMNs to adhere to fibrinogen-coated surfaces via CD11c/CD18 (7,8), while phorbol dibutyrate stimulates PMNs to adhere to these surfaces via CD11b/CD18 (8,9), prompted the examination of the effects of different chemoattractants on PMN migration through three
30 dimensional matrices composed of fibrin, collagen IV or Matrigel, and through gels formed by thrombin treatment of cell-free plasma.

Experimental Procedures

35

Reagents

Human monocyte recombinant IL-8 (Ser-IL-8)₇₂ and TNF- α were from Upstate Biotechnology Incorporated (Lake Placid, NY). LTB₄, fMLP and Ficoll-Hypaque were from Sigma (St. Louis, MO). Rhodamine conjugated polyethylene glycol was prepared as described (10).

Preparation of Boyden-type chemotaxis chambers

Becton-Dickinson cell culture inserts (pore sizes 3 or 8 μ m; Franklin Lakes, NJ) were overlaid with the following proteins:

Fibrin gels: 1 Unit of thrombin (a gift from Dr. John Fenton, Albany Medical College, Albany, NY), in 5 μ l of PBS was added first to each insert. 0.1 ml phosphate buffered saline supplemented with Ca²⁺ and Mg²⁺ (PBS) containing 100 μ g commercial grade fibrinogen (Calbiochem. Inc., San Diego, CA) or purified fibrinogen [a gift from Dr. Jeffery Weitz, (MacMaster University, Hamilton, On.)] was then placed into each 8.2 mm diameter insert on top of the thrombin. The mixture was incubated at 37°C for 5 min to allow fibrin gel formation (determined by visual inspection). 1 Unit PPACK (Calbiochem Inc., San Diego, CA; 10⁻⁵ M final concentration), in 100 μ l medium was added to each insert to inhibit thrombin, and gels were washed with 250 μ l PBS to remove inactivated thrombin. The fibrin gels formed were about 1 mm thick as measured under a dissecting microscope.

30

Collagen type IV and Matrigel matrices: 0.1 ml PBS containing 100 μ g human placental collagen IV (Fluka Chemical Corp., Ronkonkoma, NY), or 80 μ g of reconstituted basement membrane proteins (Matrigel, Collaborative Research, Bedford, MA), was placed into each insert and allowed to gel at room temperature for 24 hrs.

35

Clotted Plasma: Whole blood was collected and the cellular components were removed by centrifugation. The resulting plasma was mixed with an equal volume of PBS, and 100 μ l of this mixture was placed into each insert
5 containing thrombin and allowed to clot as described above. One unit of PPACK in 100 μ l PBS then was added and the inserts were washed with 250 μ l of PBS.

Fibrinogen or fibronectin: 0.1 ml of PBS containing 100
10 μ g/ml fibrinogen or fibronectin (New York Blood Center, New York, NY), was placed into each insert (pore size 3 μ m). Inserts were incubated at 37°C for 60 min and washed with 250 μ l of PBS. Filters coated with fibrinogen or
15 fibronectin were diffusely fluorescent as visualized by epifluorescent microscopy when incubated with the corresponding antibody [fluorescein-labeled anti-fibrinogen, or anti-fibronectin monoclonal antibodies (Cappel, Malvern, PA)], while uncoated filters, or
20 filters incubated with fluorescein-labeled antibody of the opposite specificity, were not.

PMN migration

PMNs were prepared from fresh heparinized blood from
25 healthy adult volunteers by sedimentation on Ficoll-Hypaque gradients. Contaminating red blood cells were removed by hypotonic lysis, as described (7). The purity of PMN isolated by this method is >95% as determined by Wright-Giemsa staining (7). 10^6 PMNs in 250 μ l of PBS
30 supplemented with 5.5 mM glucose and 0.1% human serum albumin (PBSG-HSA), were placed in the upper compartment of each insert and incubated for 0-6 hrs at 37° C in a humidified atmosphere containing 95% air/5% CO₂. At the
times and concentrations specified, chemoattractants
35 /cytokines were added to the top or bottom compartment in 250 μ l of PBSG-HSA. At the end of the incubation, the chambers were shaken to dislodge PMNs from the lower

surface of the inserts. The medium in each lower compartment was collected and its content of PMNs was determined using either a Coulter Counter or a hemocytometer. Both methods gave similar results. Counts
5 are expressed as the average number of PMNs that migrated into the lower compartment. Unless otherwise indicated, all values reported are the average of six data points from at least 3 independent experiments.

10 Confocal Microscopy

PMNs were suspended in medium containing 10 μ M calcein/acetoxymethyl ester (Molecular Probes, Eugene, OR), 0.02% (w/v) pluronic F-127 (Molecular Probes,
15 Eugene, OR), 2% heat inactivated calf serum (HyClone, Logan, UT), and 0.2% DMSO, and mixed gently for 40 min at room temperature. Cells loaded with dye under these conditions exhibited no changes in motility (Mandeville and Maxfield, unpublished observations). The calcein-
20 loaded cells were rinsed in PBSG-HSA and added to inserts containing fibrin gels in the presence or absence of TNF, fMLP, LTB₄ or IL-8. Following incubation with PMNs, fibrin-coated filters were gently cut from their inserts using a razor blade, transferred to a glass slide,
25 immersed in PBSG-HSA and covered with a glass coverslip. Migration of calcein-loaded PMNs through fibrin was analyzed using a Dialux 20 X microscope (Leitz) fitted with a K2 Bio confocal scanning optical attachment using a Nipkow spinning disk. The microscope was equipped with
30 an image intensifier, charge coupled device camera and video frame averager. The surface of the fibrin gel was identified using reflection interference contrast microscopy. Cells were imaged with a Plan-neofluor 25 X fluorescence objective (NA= 0.8) using fluorescein optics
35 (490 nm excitation, 525 emission) and a spinning disk with pinhole apertures. Serial confocal optical sections were acquired at 1 μ m intervals, digitized using the

VolCon program (a PC-based image processing package, Indec Systems, Capitola, Ca,). Three dimensional images were volume rendered using Microvoxel software (Index Systems), after passing data through a 3x3x3 Gaussian convolution filter. Each experiment was repeated at least twice using duplicate samples.

PMN adhesion to fibrin-coated surfaces

Fibrin coated Terasaki tissue culture plates were prepared as described (10). 5 μ l of PBSG-HSA, containing PMNs (10^6 /ml) and the indicated chemoattractant, was added to each well of the plate. Plates were incubated at 4° for 30 min to allow PMNs to settle to the bottom of the wells and warmed to 37° for 15 min to allow PMNs to adhere. Non-adherent cells were removed as described (7), and 2.5% glutaraldehyde in PBS added to fix the adherent PMNs. PMNs adherent to each well were enumerated using a phase-contrast microscope. Values reported are the mean number of PMNs adherent to six wells from a representative experiment (n=3).

Exclusion of rhodamine-labeled polyethylene glycol from zones of adhesion of PMNs to protein-coated surfaces

10 kDa rhodamine labeled polyethylene glycol (Rh-PEG), prepared and used as described previously (10), does not bind to untreated glass, tissue culture plastic, or to cell membranes. Rh-PEG binds avidly to protein-coated surfaces, and can be detected easily by its fluorescence. Individual wells on glass microslides (Carlson Scientific, Peotone, IL) were coated with either fibrin, Matrigel or collagen IV in a manner similar to that for coating cell culture inserts except that 20 μ l of the various solutions were used per well. 20 μ l of PMNs (10^6 cells/ml in PBSG-HSA) were added to each well and PMNs were allowed to adhere for 15 mins at 37°. The cells

were washed in PBS, fixed with 3.7% paraformaldehyde in PBS for 10 min, washed again with PBS, and further incubated with 10 kDa Rh-PEG at room temperature for 60 min. The preparation then was washed with PBS and immediately observed by phase and fluorescent microscopy at 400X magnification. Average values from three different experiments are reported as the percentage of PMNs that excluded Rh-PEG from zones of adherence between the cells and the underlying matrix.

10

Degradation of ^{125}I -labeled fibrin gels

1.0 ml PBS containing 1 mg human fibrinogen, 1 mCi of Na^{125}I (NEN, Boston, MA), and 1 Iodobead (Pierce, Rockford, IL) was incubated for 15 mins on ice. ^{125}I -fibrinogen was separated from ^{125}I by gel filtration over a Speedy Desalting Column (Pierce). >97% of the ^{125}I recovered in the fibrinogen-containing fractions was precipitable with 20% trichloroacetic acid. 5 μl PBS containing 1 Unit of thrombin, followed by 0.1 ml PBS containing 10^6 cpm of ^{125}I -fibrinogen ($\sim 10 \mu\text{g}$) and 100 μg unlabeled fibrinogen were added to each insert, as described above. The resulting ^{125}I -labeled fibrin gels were treated with PPACK, washed, and incubated with 10^6 PMNs as described in the text. At various times after PMN addition the medium was removed from the upper and lower compartments, and added to 0.1 ml of PBS containing 10 mg/ml bovine serum albumin (BSA). Ice-cold trichloroacetic acid was added to a final concentration of 20% and samples were centrifuged to sediment acid insoluble materials. TCA soluble and insoluble materials were separated by centrifugation and ^{125}I in each fraction was determined using an LKB minigamma counter.

35

Results

IL-8 and LTB₄, but not TNF or fMLP, promote the migration

004784-102299

of PMNS through fibrin gels

PMNs were placed into the upper compartment of inserts containing fibrin gels. IL-8, LTB₄, fMLP, or TNF was placed in the medium in the lower compartment and the chambers were incubated at 37°C for 6 hrs. IL-8 or LTB₄ stimulated 12-25% of PMNs to migrate through the fibrin gels and into the lower compartment. In the absence of a chemoattractant or in response to various concentrations of TNF (10^{-9} - 5×10^{-6} M) or fMLP (10^{-10} - 10^{-6} M), fewer than 0.3% of the PMNs migrated through fibrin gels into the lower compartments (Figures 1A and 2). Moreover, PMNs did not migrate through fibrin in response to the addition of 2-10% zymosan-activated human plasma (C5a) in the lower compartment.

PMNs stimulated by IL-8 or LTB₄, but not by TNF or fMLP, migrated through fibrin gels formed by thrombin treatment of commercial-grade fibrinogen (Figure 1A) or of purified fibrinogen, or through plasma gels formed by thrombin treatment of human plasma (Figure 1B). Moreover, the presence of 20% human serum in the medium in both upper and lower compartments did not alter PMN migration through fibrin gels in response to IL-8, nor did the presence of serum promote PMN migration through fibrin gels in response to TNF or fMLP. That PMNs migrate through fibrin gels in the presence of human serum, and through gels formed from whole human plasma, indicates that IL-8 promotes PMN migration through fibrin gels containing the complex mixture of plasma proteins found under physiological conditions.

The percent of PMNs that migrated through fibrin gels varied with the concentration of IL-8 or LTB₄ placed in the bottom compartment (Figure 2B). Maximal PMN migration occurred with 0.7×10^{-7} M IL-8 or 0.2×10^{-7} M LTB₄ (Figure 2B). PMN migration decreased dramatically

when IL-8 was used at concentrations $> 10^{-7}$ M, consistent with the report of Smith et. al. (11) that high concentrations of IL-8 desensitize PMNs. In contrast, there was no indication of PMN desensitization in response to supra-optimal concentrations of LTB4 (Figure 2B).

To determine whether IL-8 and LTB4 promote PMN migration through fibrin gels by stimulating chemotaxis or chemokinesis we performed a checkerboard-type analysis (12). Few PMNs migrated through fibrin gels when IL-8 or LTB4 was placed in the upper compartment, or when the upper and lower compartments contained equal concentrations of IL-8 or LTB4 (Figures 1A and 1B). As the difference in IL-8 or LTB4 concentrations between the upper and lower compartments decreased, the number of PMNs that migrated through the fibrin gels also decreased (Figures 3A and 3B). These results indicate that PMN migration through fibrin gels in response to IL-8 or LTB4 reflects chemotaxis, not chemokinesis.

Between 25-50% more PMNs migrated through fibrin in response to LTB4 than to IL-8. It is unlikely that this difference reflects the response of different PMN subpopulations to LTB4 vs IL-8 since the same percentage of PMNs traversed fibrin gels in response to optimal concentrations of both LTB4 and IL-8 in the lower compartment as to LTB4 alone. Other investigators have reported that only 20-50% of PMNs migrate through filters (13), natural matrices, and cellular barriers (14), when stimulated by these chemoattractants. Since virtually all PMNs orient and crawl on surfaces when exposed to the chemoattractants (3), it is evident that all PMNs responded to them. The reason(s) why only a fraction of PMNs migrate through artificial or natural barriers in response to chemoattractants is unknown.

PMNs migrated through fibrin gels more rapidly in response to an optimal concentration of LTB₄ than to an optimal concentration of IL-8 (Figure 4). Ten percent of LTB₄-stimulated PMNs migrated through fibrin gels within
5 2 hrs while fewer than 0.5% of IL-8-stimulated PMNs migrated through these gels in this time period (Figure 4). By 6 hrs, maximal numbers of PMNs had migrated through fibrin gels in response to either IL-8 or LTB₄.

10 To visualize the interactions of chemoattractant-stimulated PMNs with fibrin gels, PMNs prelabeled with calcein (15), were added to the upper compartment of inserts containing fibrin gels. Chemoattractants were added to the medium in the lower compartment, the
15 chambers were incubated at 37°C, and at the times indicated the fibrin-coated filters were removed and examined by confocal microscopy. After a 1 or 4 hr incubation with fMLP or TNF, almost all the cells remained on the gel's surface; fewer than 5% of TNF- or
20 fMLP-stimulated PMNs penetrated a short distance into the fibrin gels; (Figures 5A, 5B, 5C, 5D, 5E, and 5F). In contrast, greater than 80% of IL-8-stimulated PMNs migrated deeply into the fibrin gels after a 4 hr incubation (Figures 5A, 5B, 5C, 5D, 5E, and 5F). Greater
25 than 80% of LTB₄-stimulated PMNs began to migrate into the fibrin gel after 1 hr, while few IL-8 stimulated PMNs penetrated the fibrin at this time. These results show that TNF and fMLP do not promote PMN invasion of fibrin, and that LTB₄ stimulates PMNs to enter fibrin gels more
30 rapidly than IL-8. The latter finding is consistent with the more rapid transit of fibrin gels by LTB₄- than IL-8-stimulated PMNs described in Figure 4.

To further examine whether proteolysis of fibrin
35 accounted for the selective ability of IL-8- or LTB₄-stimulated PMNs to traverse these gels, the release of ¹²⁵I-labeled products was measured from ¹²⁵I-fibrin

incubated with PMNs for 6 hrs at 37°C in the presence or absence of each of these chemoattractants. The rate and extent of release of ¹²⁵I-labeled acid soluble and acid precipitable products was similar for all four
5 chemoattractants (Figure 6). Even in the presence of 20% serum, chemoattractant-stimulated PMNs released no more ¹²⁵I-labeled products than unstimulated PMNs. These results suggest that fibrin degradation does not account for the selective ability of LTB₄- and IL-8-stimulated
10 PMNs to traverse fibrin gels.

LTB₄, IL-8, TNF AND fMLP promote pmn migration through gels formed of matrigel and collagen IV

15 To confirm that the inability of TNF-, fMLP-, or zymosan-activated human plasma- stimulated PMNs to migrate through fibrin gels reflected an effect of the interaction between the fibrin matrix and chemoattractant-stimulated PMNs, and not a general effect
20 of any three dimensional matrix on PMNs stimulated with these chemoattractants, the ability of TNF, zymosan activated human plasma and fMLP to promote PMN migration through gels composed of basement membrane proteins (Matrigel) or collagen IV was examined (Figures 7A and
25 7B). TNF, fMLP, IL-8, zymosan-activated human plasma, or LTB₄ added to the bottom chamber stimulated PMN migration through these gels (Figure 7A). To determine whether fibrin affected PMN migration through collagen matrices, inserts coated with collagen IV gels were incubated with
30 fibrinogen and thrombin to form fibrin sandwich on top of the collagen gels, and washed with PPACK-containing buffer. PMNs were added to the upper compartment and TNF to the lower compartment. The presence of fibrin prevented PMN migration through the collagen gels in
35 response to TNF by about 75% (Figure 7A). These results confirm that the effect of fibrin is selective and that it affects PMN migration in response to a specific subset

of chemoattractants.

To determine whether protein monolayers had the same effects on PMN migration as gels, inserts were coated with fibrinogen or fibronectin. The adsorption of these proteins to the filters that form the floor of the inserts was confirmed by immunofluorescence microscopy, as described in Experimental Procedures. fMLP, TNF, IL-8 and LTB4 all promoted PMN migration through filters to which fibrinogen or fibronectin had been adsorbed (Figure 7B).

PMNs adhere more closely to fibrin in response to fMLP or TNF than to LTB4 or IL-8

Is there a relationship between the ability of a chemoattractant to stimulate PMN migration through fibrin and its ability to promote close apposition of PMNs to fibrin? PMNs were incubated on fibrin-coated surfaces in the presence or absence of a chemoattractant for 15 min at 37°C. As expected, TNF, fMLP, LTB4 and IL-8 were equally effective in stimulating PMN adherence to fibrin (>200 chemoattractant-stimulated PMNs vs ~10 unstimulated PMNs adhered per mm²). The closeness of PMN adhesion to fibrin was evaluated by the ability of 10 kDa Rh-PEG (8,10), to penetrate into the zones of adhesion between chemoattractant-stimulated PMNs and fibrin. By this measure 70-80% of adherent TNF- or fMLP-stimulated PMNs excluded Rh-PEG from their zones of contact with the fibrin (Figure 8). In contrast, only about 15% of adherent LTB4- or IL-8-stimulated PMNs formed adhesive zones that excluded Rh-PEG (Figure 8). Furthermore, the adhesive zones formed by this 15% of IL-8-stimulated PMNs were at least 50% smaller in area than those formed by TNF- or fMLP-stimulated PMNs as judged by the area from which Rh-PEG was excluded.

Previous studies (10) showed that the exclusion of fluorescein-conjugated F(ab)₂ anti-fibrinogen from zones of contact between ADP-stimulated platelets and fibrinogen-coated surfaces is a useful measure of the closeness of apposition between platelet membranes and the substrate. Therefore, the exclusion of fluorescein-conjugated F(ab)₂ anti-fibrin from zones of contact between LTB₄- or IL-8-stimulated PMNs and fibrin was used as a measure of the interaction of these cells with fibrin-coated surfaces. About 50% of fibrin-adherent LTB₄- or IL-8-stimulated PMNs formed adhesive zones that excluded this high molecular weight (100 kDa.) probe. As expected from studies with Rh-PEG (Figure 8), >99% of fibrin-adherent TNF- or fMLP-stimulated PMNs excluded fluorescein-conjugated F(ab)₂ anti-fibrin from their zones of contact with fibrin (data not shown). Thus, LTB₄- or IL-8- stimulated PMNs adhere more closely to fibrin than unstimulated PMNs, even though these chemoattractants do not promote the very close apposition characteristic of fMLP- or TNF-stimulated PMNs.

The effect of combinations of chemoattractants on migration of PMNS through fibrin gels

The inability of fMLP- or TNF-stimulated PMNs to migrate through fibrin can be interpreted in at least two ways. First, fibrin blocks the capacity of PMNs to respond to fMLP or TNF. This seems unlikely since fMLP and TNF promote close apposition between PMNs and fibrin coated surfaces (Figure 8). Second, fMLP or TNF signal PMNs to become sessile when they interact with fibrin. To examine the second possibility, the effects of combinations of chemoattractants on PMN migration through fibrin gels were monitored (Figures 9A and 9B). The presence of fMLP in the bottom compartment of the inserts reduced PMN migration through fibrin gels in response to IL-8 or LTB₄ in a concentration dependent fashion.

Higher concentrations of fMLP were required to effect equal inhibition of migration of LTB₄- stimulated PMNs vs IL-8 stimulated PMNs (Figure 9B). TNF had a small, reproducible, but statistically insignificant inhibitory effect on the migration of PMNs in response to IL-8 and no measurable effect on PMN migration in response to LTB₄ (Figure 9A). Thus, fMLP selectively reduced PMN migration through fibrin gels in response to IL-8 or LTB₄ (Figure 9B).

The effects of combinations of chemoattractants on formation of close apposition of adhesion of PMNs with fibrin were also examined. fMLP in combination with IL-8 or LTB₄ induced about 50% of PMNs to form zones of adhesion that excluded 10 kDa. Rh-PEG (Figure 8). In contrast, only 15% of PMNs stimulated with IL-8 or LTB₄ alone formed close zones of adhesion (Figure 8). Thus, the capacity of PMNs to form close zones of adhesion on fibrin was inversely associated with the capacity of PMNs to migrate through fibrin gels under conditions where PMNs were stimulated with TNF, fMLP, IL-8 or LTB₄ given alone or with fMLP in combination with IL-8 or LTB₄.

To determine the mechanism by which fibrin blocks PMN migration in response to fMLP, the effects of anti-integrin antibodies were tested (Figures 10A and 10B). PMNs incubated with anti- β_2 integrin antibodies (2 μ g/ml) or the peptide GRGDSP (SEQUENCE ID NO. 1) (1 mg/ml), but not GRGESD (SEQUENCE ID NO. 2), migrated through fibrin gels in response to fMLP. Control experiments showed that anti- β_2 antibodies did not affect LTB₄-stimulated PMN migration through fibrin. These studies show that interactions between PMN β_2 integrins and matrix-associated ligands regulate PMN migration. They suggest that fMLP, but not LTB₄ signals binding of β_2 integrins to β_2 ligands (e.g. RDG) on fibrin. These studies also suggest that ligation of β_2 integrins signals fMLP-

stimulated PMN to become sessile, and that by blocking 3. integrins with antibodies or peptides, PMNs are able to migrate into tissue sites containing fibrin, from which PMN would otherwise be excluded.

5

Discussion

Matrix proteins modulate cellular responses to hormones, cytokines, and growth factors

10

Matrix proteins exert profound effects on adhesion, differentiation, migration, and/or secretion of epithelial cells (16,17), endothelial cells (18), neurons (19,20) and leukocytes (7,9,21-27). Matrix proteins also affect the ability of many types of cells to respond to hormones, growth factors, and cytokines (28,29). The findings that some chemoattractants (e.g., fMLP, TNF, C5a), promote PMN migration in the context of two types of extracellular matrix proteins (e.g., matrigel and collagens IV) (Figures 5A, 5B, 5C, 5D, 5E, 5F, 7a, and 7B), and PMN immobilization in the context of another (e.g., fibrin) (Figures 1A, 1B, 2A, 5A, 5B, 5C, 5D, 5E, and 5F), are the first to show that specific matrix proteins regulate leukocyte chemotaxis. They show that fibrin gels, fibrin-impregnated collagen gels, and fibrin-containing plasma clots present selective barriers to the migration of fMLP- or TNF-stimulated PMNs and that chemotaxis of PMNs through three dimensional matrices is regulated by both the specific chemoattractant and the protein composition of the matrix with which the cells are in contact.

30

Matrix proteins regulate PMN adhesion, phagocytosis and secretion

35

Previous studies (7,9,21) have shown that TNF or phorbol ester stimulated PMNs adhere to fibrinogen-coated

surfaces via different beta-2 integrins (CD11b/CD18 vs CD11c/CD18, respectively) and Lundgren-Akerlund et al. (22), and Thompson and Matsushima (23), have reported that fMLP stimulated PMNs adhere to protein coated surfaces with different efficiencies depending on the matrix protein used to coat these surfaces. With respect to phagocytosis, Pommier et al. (24), and Wright et al., (25) showed that the interaction of fibronectin with its β_1 integrin activates complement receptors (CD11b/CD18) on monocytes and PMNs to phagocytose C3bi-coated particles. With respect to secretion, Monboisse et al., (26,27) reported that the interaction of unstimulated or chemoattractant- stimulated PMNs with collagen I-coated surfaces induces the secretion of proteolytic enzymes and O_2^- . In contrast, preincubation of PMNs with collagen IV blocks the ability of collagen I and of fMLP to stimulate resting PMNs to secrete these products (26,27). Similarly, adhesion of TNF- stimulated PMNs to extracellular matrix proteins that express Arg-Gly-Asp motifs enhances PMN secretion (30). The findings reported here add chemotaxis to the list of leukocyte functions modulated by their contact with matrix proteins.

Relationship between strength of adhesion, closeness of PMN apposition to the substrate, and PMN migration

DiMilla et al (31), have explored the relationship between strength of cell adhesion to a substrate and cell migration by following the spontaneous migration of human smooth muscle cells on surfaces that had absorbed varying concentrations of fibronectin or collagen IV. Under the conditions of their experiments, the rate of cell migration was maximal at an intermediate level of cell-substratum adhesiveness. Goodman et al. (32), found a similar biphasic relationship between the movement of murine skeletal myoblasts and the absorbed concentration

of laminin on the substrate.

While the strength of PMN adhesion to fibrin was not measured directly, the "closeness" of apposition between PMNs' matrix-adherent surfaces and matrices containing different proteins was examined by measuring the permeability of zones of contact between PMNs and the underlying matrix to macromolecular probes. "Close" apposition is defined as the exclusion of 10 kDa Rh-PEG from zones of contact between the PMNs' substrate-adherent membranes and the matrix, and "loose" apposition as permeation of 10 kDa Rh-PEG into these zones. These results show that chemoattractants, such as IL-8 and LTB₄, elicit "loose" apposition between PMNs and fibrin gels and promote PMN migration through these gels. Chemoattractants, such as fMLP and TNF, that signal "close" apposition between PMNs and fibrin gels do not promote PMN migration through these gels. This correlation was further supported by the findings that PMNs stimulated by any of these chemoattractants formed loose zones of adhesion (e.g., permeable to 10 kDa Rh-PEG) on collagen IV or Matrigel (Figure 8), and migrated through these matrices (Figure 7A); and that fMLP induced LTB₄ or IL-8 stimulated PMNs to form close zones of apposition to fibrin and cease migration (Figures 8, 9A and 9B). Thus, there is an inverse association between close PMN interaction with a matrix protein and the ability of PMNs to migrate through gels containing it. These findings suggest that "close" and "loose" apposition between PMNs and matrix proteins as defined here, are functionally equivalent to very strong and intermediate adhesion between cells and matrix, respectively, as defined by DiMilla et al (31).

35 Fibrin degradation is not required for PMN chemotaxis

The zones of close apposition formed between fMLP- or

00784 0000
SECRET 448460

TNF-stimulated PMNs and fibrin gels are impermeant to molecules of >10 kDa thereby excluding virtually all plasma protease inhibitors such as alpha₁ anti-plasmin and alpha₂ macroglobulin. Therefore, leukocyte proteases
5 secreted into these zones function virtually uninhibited (33). In contrast, IL-8- or LTB₄-stimulated PMNs adhere more loosely to fibrin-gels. Under these conditions, plasma protease inhibitors should have ready access to zones of contact with the substrate and inhibit the
10 action of leukocyte proteases. Thus, fMLP- or TNF-stimulated PMNs might be expected to digest fibrin gels more efficiently than IL-8- or LTB₄-stimulated PMNs. This was not observed (Figure 6). There were no significant differences in the amount of radiolabel released from
15 ¹²⁵I-labeled fibrin by migrating LTB₄- or IL-8-stimulated PMNs vs sessile fMLP- or TNF-stimulated PMNs, even in the presence of 20% serum. These findings suggest that PMNs that migrate through fibrin gels in response to IL-8 and LTB₄ do so by mechanisms other than proteolyzing these
20 gels. Lanir et al., (34) came to a similar conclusion in their studies of guinea pig macrophage migration through fibrin gels.

That fMLP and TNF promote PMN migration through
25 fibrinogen-coated filters (Figures 7A and 7B), is probably related to the observations that fMLP-stimulated PMNs efficiently degrade substrate-adherent proteins including fibrinogen (33), and fibronectin (35), thereby removing these proteins from the substrate and
30 facilitating PMN movement.

How do matrix proteins regulate leukocyte chemotaxis?

The results shown in Example 1 indicate the following:
35 Different chemoattractants activate different subsets of PMN integrins to bind to ligands on matrix proteins (7-9). The interaction of each type of activated PMN

integrin with its cognate ligand on a matrix protein specifies a distinct set of cellular migratory or sessile responses. These responses may result from direct interaction of a matrix protein with the activated
5 integrin or by signals sent by the activated integrin to other integrins on the same cell. There are several instances where ligation of one type of integrin by matrix proteins modulates the activity of another type of integrin. As described above, Pommier et al., (24) and
10 Wright et al. (25) showed that ligation of β_2 integrins by fibronectin activates the β_2 integrin CD11b/CD18, (complement receptor 3) on monocytes and PMNs to phagocytose C3bi-coated particles. It was previously shown that ligation of $\alpha_5\beta_1$ on platelets by fibronectin
15 stimulates platelets to form close zones of apposition with fibrinogen (10). Hotalia et al, (36) reported that ligation of $\alpha_5\beta_1$ integrin by RGD peptides induces the expression of matrix metalloproteinases by fibroblasts, whereas ligation $\alpha_4\beta_1$ integrin by intact fibronectin
20 suppresses matrix metalloproteinase expression.

In vivo inflammatory stimuli elicit the generation of multiple chemoattractants/cytokines. The present findings show that a hierarchy of cellular responses is
25 generated when different combinations of chemoattractant receptors are stimulated simultaneously. Signals generated by fMLP receptors appear to override signals produced by LTB4 or IL-8 receptors, thereby blocking the ability of LTB4 or IL-8 to stimulate PMN migration
30 through fibrin gels (Figure 8). In contrast, signals generated by TNF receptors have no effect on LTB4-stimulated PMN migration through fibrin gels, and a very weak inhibitory effect on IL-8-stimulated PMN migration through these gels (Figure 8).

35 PMN chemotaxis through three dimensional lattices composed of extracellular matrix proteins is regulated

both by signals initiated by a specific chemoattractant, and by signals generated when specific PMN receptors interact with their cognate ligands on extracellular matrix proteins. Viewed from this perspective each of
5 the many different chemoattractants provides PMNs both with general instructions to crawl, and with specific instructions to become sessile when specific receptors on these cells contact their cognate ligands on matrix proteins. Thus, chemoattractants provide tissue
10 localization instructions for PMNs. It seems likely that chemoattractants also provide such instructions to other types of leukocytes as well.

PMNs stimulated with zymosan-activated human plasma (C5a)
15 did not migrate across fibrin-coated inserts but did migrate across matrigel-coated inserts. Thus, C5a, like fMLP and TNF, signals PMNs to stop migrating when they contact fibrin.

20 Example 2

The inhibitory effects of extracellular matrix proteins on chemotaxis of leukocytes (7,8,9,65) prompted the examination the effects of tenascin on these processes.
25 The present findings show that tenascin blocks chemotaxis of polymorphonuclear and mononuclear phagocytes across reconstituted basement membrane (Matrigel)-coated filters in a β_1 integrin-dependent process.

30 Experimental Procedures

Cells

Polymorphonuclear leukocytes (PMN), were prepared as
35 described (7) from heparinized human blood by sedimentation on Ficoll-Hypaque gradients. Contaminating red blood cells were removed by hypotonic lysis. The

purity of PMN isolated by this method was >95% as determined by Wright-Giemsa staining.

Mononuclear cells were isolated by centrifugation of
5 heparinized human blood on Ficoll-Hypaque gradients as
described (65,66). The mononuclear cell fraction was
resuspended in RPMI 1640 medium supplemented with 10%
pooled human serum or autologous serum and used
10 immediately for monocyte migration studies. For some
experiments, monocytes were obtained by centrifugation of
whole blood or of white blood cells concentrated from a
unit of blood (leukopak), on Nycodenz gradients as
described (39). More than 90% of the nucleated cells
15 obtained by this Nycodenz method were monocytes, as
assessed by their ability to phagocytose IgG-coated red
blood cells.

Cultured monocytes were prepared by allowing 10^7 total
mononuclear cells, suspended in 10 ml of RPMI 1640 medium
20 supplemented with 10% pooled human serum (1640+HS), or
10% autologous serum (1640+AS), to adhere to Falcon T-150
tissue culture Petri dishes for 2 h at 37° C. Non-
adherent cells were removed by washing, leaving an
adherent cell population consisting of greater than 98%
25 monocytes as measured by their capacity to phagocytose
IgG coated sheep red blood cells. For migration studies,
monocytes were maintained in culture for 24 h in RPMI
1640 + HS or AS, and detached from the dishes by gentle
pipetting of 10 ml of ice cold phosphate buffered saline
30 (without Ca^{2+} or Mg^{2+}) containing 1.0 mM EDTA. The cells
recovered were resuspended in RPMI-1640 + HS as described
(65).

Protein-coated filters

35

Cell culture inserts containing polyethylene
terephthalate filters, 8- μm pore size (Becton-Dickinson),

5 were overlaid with 0.1 ml of Matrigel (20-25 μ g protein/filter) (Collaborative Research, Bedford, MA), and incubated at room temperature until they dried. These Matrigel-coated filters were washed with phosphate buffered saline containing 1.0 mM Mg^{2+} and 1.0 mM Ca^{2+} (PBS). 0.1 ml of a PBS solution (pH 7.2) containing the indicated amount of purified chick brain tenascin was added to some of the inserts. The filters were incubated at room temperature until they dried. These protein-coated filters were washed again with PBS and used within 10 12 h for cell migration studies. To prepare collagen I-coated inserts, filters were coated with rat tail collagen I (ICN Biochemicals, Costa, Mesa, CA) (400 μ g/ml in PBS), by adding 0.1 ml of this solution to an 15 insert and incubating the inserts at room temperature for 24 h. Some of these collagen I-coated filters were then incubated with tenascin as described above.

Cell migration

20 **Monocytes:** Cell culture inserts were placed in 16 mm wells containing 0.5 mls of RPMI-1640+HS or AS in the presence or absence of a chemoattractant. 0.5 ml of RPMI-1640+HS or AS serum containing between $2-10 \times 10^5$ 25 mononuclear phagocytes was added to the upper chamber of the inserts and the inserts were placed in a humidified CO_2 incubator at $37^\circ C$. After 24 h the medium in the lower chamber was recovered and its cell content assayed using either a Coulter counter or a hemocytometer. No 30 significant increase was observed in the number of monocytes that migrated into the lower compartment at times greater than 24 h. Cell counts reported are the average number of cells recovered from the medium in the lower compartment of chemotaxis chambers. Over 90% of 35 the cells in the lower chamber were identified as monocytes based on their morphology, their capacity to phagocytose IgG coated sheep red cells, and their

staining with fluorescein-conjugated anti $\alpha\beta$ monoclonal antibody (Oncogene Sciences, Uniondale, NY). Unless otherwise indicated, all values are the average of duplicate samples run in parallel in a representative experiment. Each experiment was repeated at least three times with similar results.

PMN: 250 μ l of PBS [supplemented with 5.5 mM glucose and 0.1% human serum albumin (HSA) (PBSG-HSA)] containing 1×10^6 PMNs was placed in the upper compartment of each insert. 250 μ l of PBSG-HSA with or without chemoattractant, as indicated, was added to the bottom compartment. The inserts were incubated for about 4 h at 37° C in a humidified atmosphere containing 95% air/5% CO₂. No further increase in the number of PMNs was observed in the lower compartment beyond 4 h. The medium in the lower compartment was collected and its content of PMN determined using a Coulter Counter, as described in Example 1.

Tenascin

To isolate tenascin, 14-day embryonic chick brains were homogenized in the presence of protease inhibitors and the extracts were clarified as previously described (61). Dry CsCl was added to a final concentration of 0.5 g/ml and the extract was centrifuged (18 h, 45,000 rpm, 20° C) in a Beckman VAC 50 rotor. The resulting density gradients were fractionated into five 8-ml fractions. The third and fourth fractions a rich source of relatively pure tenascin, were pooled, dialyzed versus 10 mM Tris pH 8.0, then incubated with chondroitin ABC lyase (Seikagaka America), in the presence of protease inhibitors (61), to degrade contaminating proteoglycans. The sample then was lyophilized, resuspended in 4 M guanidine-HCl/ 0.1 M Tris (pH 7.6), and fractionated on a 1.5 x 100 cm column containing Sephacryl S-500

(Pharmacia, Piscataway, NJ), equilibrated in the same buffer. Tenascin-rich fractions were pooled, dialyzed, lyophilized, resuspended in a small volume of guanidine buffer, and finally dialyzed extensively vs PBS. This procedure yielded large amounts of purified tenascin which migrated as characteristic 220, 200, and 190 kD polypeptides when analyzed by SDS-PAGE under reducing conditions (44). Human tenascin was obtained from GIBCO-BRL, (Grand Island, NY). To remove the detergent in the preparation, the sample was run over a gel filtration column in the presence of 4 M guanidine-HCl; the tenascin containing fractions were then dialyzed extensively vs PBS.

15 Measurement of tenascin bound to matrices

Chick tenascin was radiolabeled using chloramine T (67), and mixed with unlabeled tenascin at a 1:100 protein ratio. 250 μ l of PBS containing varying amounts of this mixture was added to inserts coated with Matrigel or collagen I. The inserts were incubated at room temperature for 4 h at 37°C in a humidified 95%air/5% CO₂ atmosphere and washed with PBS. The filters were cut from the inserts with a scalpel, and assayed for ¹²⁵I in a Beckman gamma counter.

Reagents

Monoclonal antibody P4C10 (anti- β chain of human beta-1 integrin), was from GIBCO-BRL. Fluorescein conjugated monoclonal antibody against the β chain of human beta-2 integrins (anti- β_2 -CP14F) was obtained from Oncogene Sciences (Uniondale, NY). Fluorescein conjugated anti CD11b monoclonal antibody was from AMAC Inc (Westbrook, ME). Monoclonal anti-CD11c/CD18 (LeuM5) was from Organon-Toknica Inc.(Malvern, PA). F(ab)'₂ fragments of anti-tenascin antibodies were prepared as described (46).

Chondroitin sulfate proteoglycan monomers were purified and antibodies prepared against these proteoglycan monomers as described (37). The F(ab)'₂ fragments used in the present study were prepared from total anti-proteoglycan IgG. These antibodies were not further purified by affinity chromatography and therefore recognize both 400 kD and 250 kD proteoglycan core proteins (67).

Results

Tenascin blocks chemotaxis of monocytes and neutrophils, through matrigel-coated filters

About 20% of freshly isolated human monocytes, 15% of cultured monocytes and 10% of PMNs migrated through Matrigel-coated culture inserts in response to fMLP, LTB₄, or TNF (Figures 11A, 11B, and 12). Monocytes began to appear in the lower compartment at 12 h, and reached maximum numbers by 16-24 h. PMNs began to appear in the lower compartment by 2 h, and reached a maximum by 4 h. Fewer than 2% of added monocytes or PMN, migrated into the lower compartment in the absence of a chemoattractant (Figures 11A, 11B, and 12).

Addition of chick brain tenascin to the Matrigel significantly reduced monocyte and PMN migration in response to TNF, fMLP or LTB₄ (Figures 11A, 11B and 12). The presence of tenascin had no significant effect on the limited number of monocytes that migrated in the absence of chemoattractant (Figures 11A and 11B). In contrast, tenascin further reduced the small number of PMN that migrated across Matrigel in the absence of chemoattractant (Figure 12). The extent to which tenascin inhibited chemoattractant-stimulated monocyte or PMN migration varied from 65-80% depending on the chemoattractant used (Figures 11A, 11B, and 12). The

ability of tenascin obtained from cultured human glioma cells to effectively inhibit leukocyte migration was examined. Indeed, the addition of 5 μ g of human tenascin to the Matrigel-coated filters reduced the number of monocytes or PMNs migrating in response to a chemoattractant by at least 50% (Figures 13A and 13B).

The effect of chick brain tenascin on TNF-stimulated migration of monocytes varied with the amount of tenascin added (Figure 14). Addition of about 0.75 μ g tenascin caused half maximal inhibition of TNF-stimulated monocyte migration (Fig 14). To confirm that tenascin bound to the Matrigel, Matrigel-coated inserts were incubated with varying amounts of concentrations of 125 I-labeled chick tenascin for 4 h at 37°C. The inserts then were washed with PBS and the bound radioactivity was determined. Near plateau binding of radiolabeled tenascin was obtained with the addition of 0.625-1.25 μ g of chick tenascin to the Matrigel coated filters (Figure 15). This resulted in the adsorption of about 0.2 μ g of tenascin per filter. Once bound, less than 1% of the 125 I-labeled tenascin eluted from the filters into either the upper or lower compartment of the chambers during a 4-6 h incubation at 37°C. Thus, ~99% of tenascin remained bound to Matrigel-coated filter. The capacity of tenascin to inhibit monocyte migration (Figure 14) was roughly proportional to the amount of tenascin that bound to the filter (Figure 15), indicating that tenascin bound to the Matrigel matrix, not soluble tenascin, blocked monocyte and PMN migration.

Tenascin blocks migration of monocytes through collagen I gels

The effects of tenascin on monocyte migration through another extracellular matrix, collagen I were examined. Twelve percent of TNF- and 18% of LTB₄-stimulated

monocytes migrated through cell culture inserts coated with collagen I (Figure 16). Addition of chick brain tenascin to collagen I coated inserts reduced TNF- or LTB4-stimulated monocyte migration by at least 60% (Figure 16). Binding studies with ¹²⁵I-labeled chick tenascin revealed that similar amounts of tenascin bound to collagen I-coated filters as to Matrigel-coated filters.

10 Effect of F(ab)'₂ anti-tenascin on the migration of monocytes across filters coated with matrigel and tenascin

Monocytes or PMN were added to the upper compartment of inserts coated with Matrigel alone or with Matrigel and tenascin. F(ab)'₂ anti-tenascin (2 µg/ml) was added to the medium in the upper compartment and LTB4 (10⁻⁷ M) was added to the lower compartment. F(ab)'₂ fragments of anti-tenascin antibody had no significant effect on PMN migration across filters coated with Matrigel alone (Figure 17A), but reduced monocyte migration across this matrix by about 40% (Figure 17B). However, F(ab)'₂ fragments of anti-tenascin antibody restored PMN chemotaxis across filters coated with Matrigel and tenascin to about 75% of control values (Figure 17B), and increased substantially monocyte migration across tenascin coated Matrigel (Figure 17A).

Because of their affinity for tenascin, proteoglycans may contaminate some tenascin preparations (46). Therefore, the effects of F(ab)'₂ fragments of polyclonal anti-proteoglycan on monocyte migration across filters coated with tenascin and Matrigel were examined. F(ab)'₂ anti-proteoglycan (2-5 µg/ml) did not reverse tenascin's inhibitory effect on monocyte migration across filters coated with Matrigel and tenascin, and did not significantly affect monocyte chemotaxis across filters

coated with Matrigel alone. These studies suggest that tenascin inhibits migration by interacting with monocytes and not by blocking some matrix component required for their migration.

5

Antibodies that block β_1 integrins reverse the inhibitory effects of tenascin on monocyte and pmn migration through filters coated with matrigel and tenascin

10 Endothelial cell attachment and spreading on human tenascin has been shown to be partially mediated by β_1 integrins (60). Similarly, Prieto et al. (53,54), showed that anti- β_1 integrin antibodies block the adhesion of glioma and carcinoma cell lines to tenascin. Therefore,
15 the effects of anti- β_1 antibodies on monocyte and PMN chemotaxis through filters coated with Matrigel alone or with Matrigel and tenascin were examined. Monocytes or PMNs were preincubated for 30 min at 4°C in medium containing 2 μ g/ml of the test antibody. The suspension
20 then was added to the upper compartment of the inserts.

LTB4 was added to the lower compartment and the inserts were incubated at 37°C for 24 h for monocytes or 4 h for PMN. A monoclonal antibody directed against β_1 integrins
25 (P4C10) had no effect on monocyte chemotaxis through filters coated with Matrigel alone but reversed the inhibitory effect of tenascin on monocyte migration through Matrigel/tenascin coated filters by about 50% (Figures 17A and 17B). Control experiments showed that
30 monoclonal antibody P4C10 also reversed tenascin's inhibitory effect on TNF-stimulated monocyte chemotaxis by about 60%. P4C10 reversed almost completely the inhibitory effect of tenascin on LTB4- (Figure 17B) or TNF-stimulated chemotaxis of PMN across filters coated
35 with Matrigel and tenascin.

To confirm that the effect of P4C10 was due to its

interaction with β_2 integrins, the effects of other anti-integrin antibody, $A_{II}B_{II}$, on chemotaxis of monocytes through filters coated with Matrigel and tenascin were examined. $A_{II}B_{II}$ ($2 \mu\text{g/ml}$) blocked the inhibitory effect of tenascin on monocyte chemotaxis, allowing LTB4 stimulated monocytes to migrate through Matrigel/tenascin coated filters. In contrast, an antibody (LeuM5) directed against α_x (p150/95), a member of the β integrin family found on both PMNs and monocytes, did not reverse tenascin's inhibitory effect on LTB4-stimulated chemotaxis of PMN or monocytes through Matrigel/tenascin-coated filters (Figures 17A and 17B). As expected, monoclonal antibody IB4, directed against leukocyte β_2 integrins, inhibited chemotaxis of monocytes and PMNs across filters coated with Matrigel alone or with both Matrigel and tenascin. Thus, antibodies directed against members of the β_2 integrin family did not reverse tenascin's inhibitory effect on monocyte and PMN chemotaxis. These results indicate that blocking the interaction of monocytes or PMNs with tenascin, either by masking the tenascin on the matrix with $F(ab)'_2$ anti-tenascin or by blocking β_2 integrins on the cells, reversed the inhibitory effect of tenascin on monocyte and PMN chemotaxis.

Discussion

PMNs migrate through matrices formed by, and containing, proteins that are "normal" constituents of basement membranes and of the ground substance of interstitial spaces (e.g., collagens I and IV, laminin), in response to all chemoattractants tested (fMLP, TNF, C5a, IL-8, LTB4) (68,69). In contrast, whether PMN migrate through matrices composed of, or containing, fibrin depends upon the specific chemoattractant with which they have been stimulated. For example, fMLP, TNF and C5a stimulate PMNs to adhere tightly to fibrin gels, but not to migrate

into or through them. In contrast, IL-8 and LTB₄ stimulate PMNs to migrate efficiently through these gels.

5 The capacity of specific chemoattractants to signal
cessation of migration when PMNs contact fibrin suggested
that this might be a mechanism by which these cells are
excluded from some tissue compartments, and concentrated
in others. One example, however, hardly establishes a
general principle. Therefore, other matrix proteins that
10 block PMN and monocyte chemotaxis were sought.

Tenascin inhibits PMN and monocyte chemotaxis through
collagen I or Matrigel Matrices

15 Addition of tenascin to three-dimensional matrices formed
by collagen I or Matrigel signals cessation of movement
of PMNs and monocytes in response to all three
chemoattractants tested (fMLP, LTB₄, TNF) (Figs. 11-17).
The capacity of tenascin to block chemotaxis of PMNs
20 stimulated by LTB₄ is of special note since LTB₄ promotes
PMN migration through fibrin gels (25). This finding
supports our contention that leukocyte migration through
extracellular matrix is regulated by both the proteins in
the matrix and the specific chemoattractant. It
25 demonstrates that a chemoattractant can have entirely
different effects on a single class of leukocyte,
depending upon the matrix proteins with which the
leukocyte is in contact.

30 One of tenascin's functions in adults is to inhibit PMN
and monocyte entry into specific tissue compartments

Tenascin is an unusual matrix protein. It is expressed
widely in embryonic tissues where it regulates cell
35 migration during organogenesis. Under physiological
conditions in adults, tenascin is absent from most
tissues, except lymphoid tissue (40,55), and brain (43).

However, under pathological conditions, tenascin synthesis is stimulated. It is deposited in the extracellular matrix in areas of vascular injury (57), and tumor stroma (43,63), which are also areas of fibrin deposition (59,70-73).

It is notable that tenascin and fibrin, matrix proteins deposited in and around diseased (e.g., malignant tumors), or injured tissues (e.g., atherosclerotic lesions), or areas in which T-cells concentrate (40,43,55,57,59,63,70-73), and chemically modified matrix proteins (e.g., non-enzymatically glycated collagen IV [74]), all signal phagocytic leukocytes to become sessile. Dvorak et al. (70), and Singh et al. (59) have presented evidence that tumor stroma protects the tumors from host immune effector cells. Viewed from this perspective, tenascin contributes to an immuno-inhibitory effect of tumor stroma.

β_1 integrins play no role in PMN or monocyte migration through Matrigel

Anti- β_1 integrins had no inhibitory effect on PMN or monocyte chemotaxis through Matrigel alone (Figures 17A and 17B), while antibodies directed against PMN and monocyte β_2 integrins blocked PMN and monocyte chemotaxis under all circumstances tested (75), including through Matrigel (Figures 17A and 17B). These findings suggest that β_1 integrins play no role in PMN or monocyte chemotaxis through Matrigel. These studies did not examine whether antibodies directed against β_2 integrins inhibited PMN or monocyte chemotaxis through Matrigel by blocking their adhesion to the Matrigel or by other mechanisms, such as stimulating an increase in their cAMP content (76).

On the mechanism(s) by which tenascin blocks PMN and

monocyte chemotaxis

Chemoattractants that signal PMNs to remain sessile on
fibrin gels, cause these cells to adhere more tightly and
5 in greater numbers to fibrin than chemoattractants that
promote PMN to migrate through fibrin gels. Similarly,
chemoattractants stimulate monocytes to become sessile
and adhere more tightly to glycated collagen IV than to
native collagen IV (65,74). In contrast, no increase in
10 the number of chemoattractant-stimulated PMN or monocytes
that adhered to tenascin-impregnated Matrigel over
Matrigel alone was observed. Thus, while fibrin and
glycated matrices may inhibit chemotaxis by providing
ligands to which chemoattractant-stimulated PMNs and
15 monocytes bind very tightly, and in increased numbers,
tenascin appears to exert its inhibitory effect by a
different mechanism.

β_1 integrins have been reported to promote adhesion of
20 normal and transformed cells to tenascin (53,54,60).
 $F(ab)_2$ anti-tenascin, and anti- β_1 integrins reversed
tenascin's inhibitory effect on both PMN and monocyte
chemotaxis (Figures 17A and 17B). Since β_1 integrins
appear to play no role in PMN or monocyte chemotaxis
25 through Matrigel, the most straightforward explanation
for the capacity of $F(ab)_2$ anti-tenascin and anti- β_1
integrins to block tenascin's inhibitory effect on
chemotaxis, is that the interaction of β_1 integrins on
PMN and monocytes with cognate ligands on tenascin
30 signals these cells to stop migrating.

The results of Example 1 show that β_1 integrins regulate
the migration of fMLP-stimulated PMNs through fibrin and
that antibodies or peptides that block β_1 integrins allow
35 all PMNs to migrate through fibrin gel in response to
chemoattractant that otherwise would cause PMNs to stop

652207 E484T60
migrating when they encounter fibrin. Further work is
needed to identify the cellular pathways via which β
integrins signal PMNs and monocytes to stop moving, and
to determine the physiological significance of this
5 event. Cellular pathways and physiological significance
notwithstanding, one practical consequence of these
findings is that antibodies vs PMN and monocyte β -
integrins may be therapeutically useful by facilitating
entry of these cells into tissues and body compartments
10 from which they otherwise are excluded.

Tenascin has domains (53), which are homologous to
regions in epidermal growth factor, fibronectin, and
fibrinogen. Since fibrin and tenascin block monocyte and
15 PMN migration, tenascin's fibrinogen-like terminal knob
may play a critical role in signalling leukocytes to stop
migrating.

Example 3

20 The role of β_2 integrins in PMN chemotaxis through fibrin
gels formed in cell culture inserts (pore size= $8\mu\text{m}$) has
been examined. 10^6 PMN were added to the upper
compartment of the inserts and a chemoattractant was
25 added to the lower compartment. Previous studies (Loike,
et al., J. Exp. Med. 181: 1763, 1995) showed that PMN do
not migrate through fibrin gels in response to a gradient
FMLP but do so efficiently in response to a gradient of
LTB₄. In contrast, PMN migrate through collagen gels in
30 response to either FMLP or LTB₄. To determine the
mechanism by which fibrin blocks PMN migration in
response to FMLP, the effects of anti-integrin antibodies
were tested. PMN incubated with anti- β_2 integrin
antibodies ($2\mu\text{g/ml}$) or the peptide GRGDSP (1 mg/ml),
35 but do not GRGESD, migrated through fibrin gels in
response to FMLP (Figure 10B). Control experiments
showed that anti- β_2 antibodies did not affect LTB₄-

stimulated PMN migration through fibrin. Furthermore, anti- α_v or anti- β integrin antibodies blocked PMN migration in response to either FMLP or LTB₄ (Figure 10A). These studies show that interactions between PMN

5 β_2 integrins and matrix-associated ligands regulate PMN migration. They suggest that: 1) FMLP, but not LTB₄, signals binding of β_2 integrins to β_2 ligands (e.g. RGD) on fibrin, 2) ligation of β_2 integrins signals FMLP-stimulated PMN to become sessile, and 3) chemoattractants

10 signal PMN to crawl or to become sessile, depending upon the matrix proteins with which these cells are in contact.

References

1. Rot, A. (1991). The role of leukocyte chemotaxis in inflammation. Biochemistry of Inflammation S.W. Evans and J.T. Whicher, eds). Kluwer Academic Publishers, Lancaster, 39-54.
2. Miller, M.D., and Krangel, M.S. (1992). Biology and biochemistry of the chemokines: a family of chemotactic and inflammatory cytokines. Crit. Rev. Immunol. 12:17-46.
3. Snyderman, R., and Uhing, R.J. (1992). Chemoattractant stimulus-response coupling. Inflammation: basic principles and clinical correlates. J.I. Gallin, I.M. Goldstein, and R. Snyderman, eds. Raven Press, New York. 421-439.
4. Kishimoto, T. K., and Anderson, D.C. (1992). The role of integrins in inflammation. Inflammation: basic principles and clinical correlates. J.I. Gallin, I.M. Goldstein, and R. Snyderman, eds. Raven Press, New York. 353-406.
5. Lasky, L.A., and Rosen S.D. (1992). The selectins. Carbohydrate binding adhesion molecules of the immune system. Inflammation: basic principles and clinical correlates. J.I. Gallin, I.M. Goldstein, and R. Snyderman, eds. Raven Press, New York. 407-420.
6. Downey, G.P. (1994). Mechanisms of leukocyte motility and chemotaxis. Current Opinion in Immunol. 6:113-124.
7. Loike, J.D., Sodeik, B., Cao, L., Leucona, S., Weitz, J.I., Detmers, P.A., Wright, S.D., and

000007 4482750

Silverstein, S.C. (1991). CD11c/CD18 on Neutrophils recognizes a domain at the N terminus of the A α of fibrinogen. Proc. Natl. Acad. Sci. 88:1044-1048.

- 5 8. Loike, J.D., Silverstein, R., Wright, S.D., Weitz, J.I., and Silverstein, S.C. (1992). The role of protected extracellular compartments in interactions between leukocytes, and platelets and fibrin/fibrinogen matrices. Plasminogen activation in fibrinolysis. in tissue remodeling, and in development. P. Brakman, and C. Kluft. Editors. Ann. N.Y. Acad. Sci. 667:163-172.
- 10
- 15 9. Wright, S.D., Weitz, J.I., Huang, A.J., Levin, J.M., Silverstein, S.C., and Loike, J.D. (1988). Complement receptor type three (CD11b/CD18) of human polymorphonuclear leukocytes recognizes fibrinogen. Proc. Natl. Acad. Sci. 85,7734-7738.
- 20 10. Loike, J.D., Silverstein, R., Cao, L., Solomon, L., Weitz, J.I., Haber, E., Matsueda, G.R., Bernatowicz, M.S., and Silverstein, S.C. (1993). Activated platelets form protected zones of adhesion with fibrinogen and fibronectin-coated surfaces. J. Cell Biol. 121:945-955.
- 25
- 30 11. Smith, W.B., Gamble, J.R., Clark-Lewis, I., and Vadas, M.A. (1993). Chemotactic desensitization of neutrophils demonstrates IL 8 dependent and IL-8 independent mechanisms of transmigration through cytokine activated endothelium. Immunology 78:491-497.
- 35 12. Zigmond, S.H., and Hirsch, J.G. (1973). Leukocyte locomotion and chemotaxis. New methods for evaluation, and demonstration of a cell derived chemotactic factor. J. Exp. Med. 137: 387-410.

13. Harvath L., and Leonard, E.J. (1982). Two neutrophil populations in human blood with different chemotactic activities: separation and chemoattractant binding. Infect. Immunol. 36:443-449.
14. Furie M.B., Naperstek, B.L., and Silverstein, S.C. (1987). Migration of neutrophils across monolayers of cultured microvascular endothelial cells. An in vitro model of leucocyte extravasation. J. Cell. Sci. 88:161-175.
15. Weston, S.A. and Parish, C.R. (1990). New fluorescent dyes for lymphocyte migration studies. Analysis by flow cytometry and fluorescence microscopy. J. Immunol. Meth. 133:87-97.
16. Howlett, A.R., Bissell, M.J. (1993). The influence of tissue microenvironment (stroma and extracellular matrix) on the development and function of mammary epithelium. Epithelila Cell Biol. 2:79-89.
17. Klemke, R.L., Yebra, M., Bayna, E.M., and Cheresh, D.A. (1994). $\alpha v \beta 5$ directed cell mobility but not adhesion on vitronectin. J. Cell Biol. 127:859-866.
18. Milici, A.J., Furie, M.B., and Carly, W.W. (1985). The formation of fenestration and channels by capillary endothelium in vitro. Proc. Natl. Acad. Sci. 82:6181-6185.
19. Calof A.L., and Lander, A.D. (1991). Relationship between neuronal migration and cell-substratum adhesion: laminin and merosin promote olfactory neuronal migration but are anti-adhesive. J. Cell Biol. 115:779-794.

20. Bronner-Fraser, M. (1994). Neural crest cell formation and migration in the developing embryo. FASEB J. 8:699-706.
- 5 21. Detmers, P.A., Lo, S.K., Olsen-Egbert, E., Walz, A., Baggiolini, M., and Cohn, Z.A. (1990). Neutrophil-activating protein 1/interleukin 8 stimulates the binding activity of the leukocyte adhesion receptor CD11b/CD18 on human neutrophils. J. Exp. Med. 171, 1155-1162.
- 10
22. Lundgren-Akerlund, E., Berger, E., and Arfors, K.E. (1992). Effect of divalent cations on adhesion of PMNs to matrix molecules in vitro. J. Leuk. Biol. 51: 603-608.
- 15
23. Thompson, H.L., and Matsushima, K. (1992). Human polymorphonuclear leucocytes stimulated by TNF- α show increased adherence to extracellular matrix proteins which is mediated via the CD11b/18 complex. Clin. Exp. Immunol. 90:280-285.
- 20
24. Pommier C.G., Inada, S., Fries, L.F., Takahashi, T., Frank, M.M., and Brown, E.J. (1983). Plasma fibronectin enhances phagocytosis of opsonized particles by human peripheral blood monocytes. J. Exp. Med. 157:1844-1854.
- 25
25. Wright, S.D., Licht, M.R., Craigmyle, L.S., and Silverstein, S.C. (1985). Communication between receptors for different ligands on a single cell: ligation of fibronectin receptors induces a reversible alteration in the function of complement receptors on cultured human monocytes. J. Cell Biol. 99:336-339.
- 30
- 35
26. Monboisse, J-C., Bellon, G., Randoux, A., Duffer,

- J., and Borel, J.P. (1990). Biochem. J. 270:459-462.
27. Monboisse, J-C., Garnotel, R., Bellon, G., Ohno, N., Perreau, C., Borel J.P., and Kefalides. (1994). The $\alpha 3$ chain of type IV collagen prevents activation of human polymorphonuclear leukocytes. J. Biol. Chem. 269: 25475-25482.
28. Nicosia, R.F. and Tuszynski, G.P. (1994). Matrix-bound thrombospondin promotes angiogenesis in vitro. J. Cell Biol. 124:183-193.
29. Ohno, K., and Maier., P. (1994). Cultured rat hepatocytes adapt their cellular glycolytic activity and adenylate energy status to tissue oxygen tension: influences of extracellular matrix components, insulin and glucagon. J. Cell. Physiol. 160:358-366.
30. Fuortes, M., Jen, W-W., and Nathan, C. (1993). Adhesion-dependent Protein Tyrosine Phosphorylation in Neutrophils Treated with Tumor Necrosis Factor. J. Cell Biology 120: 777-784.
31. DiMilla, P.A., Stone, J.A., Quinn, J.A., Albelda, S.M., and Lauffenburger, D.A. (1993). Maximal migration of human smooth muscle cells on fibronectin and type IV collagen occurs at an intermediate attachment strength. J. Cell Biol. 122:729-737.
32. Goodman, S.L., Risse, G., and von der Mark, K. (1989). The E8 subfragment of laminin promotes locomotion of myoblasts over extracellular matrix. J. Cell Biol. 109:799-809.
33. Weitz, J.I., Huang, A.J., Landman, S.L., Nicholson,

- 5 S.C., and Silverstein, S.C. (1987). Elastase-mediated fibrinogenolysis by chemoattractant-stimulated neutrophils occurs in the presence of physiological concentrations of antiproteinases. J. Exp. Med. 166:1836-1850.
- 10 34. Lanir, N., Ciano, P.S., Van De Water, L., McDonagh, J., Dvorak, A.N., and Dvorak, H.P. (1988). Macrophage migration in fibrin gel matrices. II. Effects of clotting factor XIII, fibronectin, and glycosaminoglycan content on cell migration. J. Immunol. 140:2340-2349.
- 15 35. Campbell, E.J., Senior, R.M., McDonald, J.A., and Cox, D.L. (1982). Proteolysis by neutrophils. Relative importance of cell-substrate contact and oxidative inactivation of proteinase inhibitors in vitro. J. Clin. Invest. 70:845-852.
- 20 36. Huhtala, P., Humpries, M., McCarthy, J., Werb Z., and Damsky, C. (1994). The RGD and CS-1 containing cell binding regions of fibronectin signal opposing effects on metalloproteinase expression via $\alpha 5\beta 1$. Mol. Biol. Cell 5:64a.
- 25 37. Balsamo J, Ernst H, Zanin MKB, Hoffman S, Lilien J. (1995). The interaction of the retina cell surface N-acetylgalactosaminylphosphotransferase with an endogenous proteoglycan ligand results in inhibition of cadherin-mediated adhesion, J. Cell Biol. 129:1391-1401.
- 30 38. Bourdon, M.A., Ruoslahti, E. (1989). Tenascin mediates cell attachment through an RGD-dependent receptor. J. Cell Biology 108:1149-1155.
- 35 39. Boyum, A., Lovhaug, D., Tresland, L., Nordlie, E.M.

(1991). Separation of leucocytes: improved cell purity by fine adjustments of gradient medium density and osmolality. Scand. J. Immunol. 34:697-712.

5

40. Chilosì, M., Lestani, M., Benedetti, A., Montagna, L., Pedron, S., Scarpa, A., Menestrina, F., Hirohashi, S., Pizzolo, G., and Semenzato, G. (1993). Constitutive expression of tenascin in T-dependent zones of human lymphoid tissues. Am. J. of Path. 143:1348-55.

10

41. Chiquet-Ehrismann, R. (1993). Tenascin and other adhesion-modulating proteins in cancer.[Review]. Sem. in Cancer Biol. 4:301-10.

15

42. Chuong, C.M., and Chen, H.M. (1991). Enhanced expression of neural cell adhesion molecules and tenascin (tenascin) during wound healing. Am. J. Pathol. 138:427-440.

20

43. Erickson, H.P. and Bourdon, M.A. (1989). Tenascin: an extracellular matrix protein prominent in specialized embryonic tissues and tumors. Ann.Rev. Cell. Biol. 5:71-92.

25

44. Grumet, M., Hoffman, S. Crossin, K.L., and Edelman, G.M. (1985). Tenascin, an extracellular matrix protein of neural and non-neural tissues that mediates glial-neuron interaction. Proc. Natl. Aca. Sci. 82:8075-9079.

30

45. Herlyn, M., Graeven, U., Speicher, D., Sela, B.A., Bennicelli, J.L., Kath, R., Guerry, D. (1991). Characterization of tenascin secreted by human melanoma cells. Cancer Res. 51:4853-8.

35

2025-04-10 10:34:10

46. Hoffman, S., Crossin, K.L., and Edelman, G.M.
(1988). Molecular forms, binding functions, and
developmental expression patterns of cytotactin and
cytotactin-binding proteoglycans, an interactive
5 pair of extracellular matrix molecules. J. Cell
Biol. 106:519-532.
47. Hoffman, S. Dutton, S.L., Ernst, H., Boackle, M.K.,
Everman, D., Tourkin, A., and Loike, J.D. (1994).
10 Functional characterization of anti-adhesion
molecules. Perspectives in Development Neurbiology
2:101-110.
48. Joshi, P., Chung, C.Y., Aukhil, I., and Erickson,
15 H.P. (1993). Endothelial cells adhere to the RGD
domain and the fibrinogen-like terminal knob of
tenascin. J. Cell Sci. 106:389-400.
49. Juhasz, I., Murphy, G.F., Yan, H.C., Herlyn, M.,
20 Albelda, S.M. (1993). Regulation of extracellular
matrix proteins and integrin cell substratum
adhesion receptors on epithelium during cutaneous
human wound healing in vivo. Am. J. of Path.
143:1458-69.
50. Mackie., E. J., Halfter, W., and Liverani, D.
25 (1988). J. Cell Biol. 107:2757-2767.
51. Mackie, E.J., Chiquet-Ehrismann, R., Pearson, C.A.,
30 Inaguma, Y.M., Taya, K., Kwarada, Y., and Sakakura,
T. (1987). Proc. Natl. Acad. Sci. 84:4621-4625.
52. Pesheva, P., Probstmeier, R., Skubitz, A.P.,
McCarthy, J.B., Furcht, L.T. and Schachner, M.
35 (1994). Tenascin-R J1 160/180 inhibits
fibronectin-mediated cell adhesion--functional
relatedness to tenascin-C. J. Cell Sci.

107:2323-33.

53. Prieto, A.L., Andersson-Fisone, C. and Crossin, K.L. (1992). Characterization of multiple adhesive and counteradhesive domains in the extracellular matrix protein cytotactin. J. Cell Bio. 119:663-78.
54. Prieto, A.L., Edelman, G.M., and Crossin, K.L. (1993). Multiple integrins mediate cell attachment to cytotactin/tenascin. Proc. Natl. Acad. Sci. USA 90:10154-8.
55. Ruegg, C.R., Chiquet-Ehrismann, R., and Alkan, S.S. (1989). Tenascin, an extracellular matrix protein, exerts immunomodulatory activities. Proc. Natl. Acad. Sci. 86:7637-7441.
56. Sakai, T., Kawakatsu, H., Hirota, N., Yokoyama, T., Sakakura, T., and Saito, M. (1993). Specific expression of tenascin in human colonic neoplasms. British Journal of Cancer 67:1058-64.
57. Sharifi, B.G., D.W. Lafleur, S.M. Schwartz, J.S. Forrester, J.A., Fagin. (1995). Expression of tenascin isoforms are selectively up-regulated following aortic balloon injury. The FASEB Journal 9: a611.
58. Shoji, T., Kamiya, T., Tsubura, A., Hatano, T., Sakakura, T., Yamamoto, M., Morii, S. (1992). Immunohistochemical staining patterns of tenascin in invasive breast carcinomas. Virchows. Arch. A. Pathol. Anat. Histopathol. 421:53-6.
59. Singh, S., Ross, S.R., Acena, M., Rowly, D.A., and Schreiber, H. (1992). Stroma is critical for preventing or permitting immunological destruction

of antigenic cancer cells. J. Exp. Med. 175:139-146.

- 5 60. Sriramaraao, P., Mendler, M., and Bourdon, M.A. (1993). Endothelial cell attachment and spreading on human tenascin is mediated by alpha 2 beta 1 and alpha v beta 3 integrins. J. Cell Sci. 105:1001-12.
- 10 61. Tourkin A., Anderson T., LeRoy EC, Hoffman S. (1993). Eosinophil adhesion and maturation is modulated by laminin. Cell Adhesion and Communication 1:161-176.
- 15 62. Wehrle-Haller, B. and Chiquet, M. (1993). Dual function of tenascin: simultaneous promotion of neurite growth and inhibition of glial migration. J. Cell Sci. 106:597-610.
- 20 63. Hiraiwa, N., Kida, H., Sakakura, T., and Kusakabe, M. (1993). Induction of tenascin in cancer cells by interactions with embryonic mesenchyme-mediated by a diffusible factor. J. Cell. Sci. 104:289.
- 25 64. Koukous, G.K., Gould, V.E., Bhattacharyya, A., Gould, J.E., Howedy, A.A., and Virtanen, I. (1991). Tenascin in normal, reactive, hyperplastic and neoplastic tissue: biological and pathological implications. Hum. Pathol. 22:636.
- 30 65. El Khoury, J., Loike, J., Cao, L., Thomas, C., and Silverstein, S.C. (1994). Macrophages adhere to glucose-modified basement membrane collagen via their scavenger receptors. J. Biol. Chem. 269:10197-10200.
- 35 66. Loike, J.D., Somes, M., and Silverstein, S.C. (1986). Creatine uptake, metabolism, and efflux in

human monocytes and macrophages. Am. J. Physiol.
251:C128.

- 5 67. Friedlander, D.R., Hoffman, S., and Edelman, G.M.
(1988). Functional mapping of cytotactin:
proteolytic fragments active in cell-substrate
adhesion. J. Cell Biol. 107:2329.
- 10 68. Lundgren-Akerlund, E., Olofsson, A.M., Bergerand,
E., and Arfors, K. E. (1993). CD11b/CD18-dependent
polymorphonuclear leucocyte interaction with matrix
proteins in adhesion and migration. Scan. J.
Immunol. 37:569.
- 15 69. Islam, L.N., McKay, I.C., and Wilkinson, P.C.
(1985). The use of collagen or fibrin gels for the
assay of human neutrophil chemotaxis. J. Immunol.
Meth. 85:137.
- 20 70. Dvorak, H.F. (1986). Tumors: Wounds that do not
heal. Similarities between tumor stroma generation
and wound healing. N. Engl. J. Med. 315:1650-1659.
- 25 71. Willhelm, O., Hafter, R., Coppenrath, E., Pflanz,
M., Schmitt, M., Babic, R., Linke, R., Gossner, W.,
and Graeff, H. (1988). Fibrin-fibronectin compounds
in Human ovarian tumor ascites and their possible
relation to the tumor stroma. Can. Res. 48:3507.
- 30 72. Strickland D.K., Kounnas, M.Z., and Argraves, W.S.
(1995). LDL receptor-related protein: a multiligand
receptor for lipoprotein and proteinase catabolism.
[Review] FASEB J. 9:890.
- 35 73. Costantini, V., Zacharski, L.R., Memoli, V.A.,
Kisiel, W., Kudryk, B.J., Rousseau, S.M., and Stump.
D.C. (1992). TI - Fibrinogen deposition and

macrophage-associated fibrin formation in malignant and nonmalignant lymphoid tissue. J. Lab. & Clin. Med. 119:124.

- 5 74. Schmidt A. M., Yan, S.D., Brett, J., Mora, R.,
Nowygrod, R., and Stern, D. (1993). Regulation of
human mononuclear phagocyte migration by cell
surface-binding proteins for advanced glycation end
products. J. Clin. Invest. 91:2155.
- 10
75. Gao, J.X., Wilkins, J., and Issekutz, A.C. (1995).
Migration of human polymorphonuclear leukocytes
through a synovial fibroblast barrier is mediated by
both beta 2 (CD11/CD18) integrins and the beta 1
15 (CD29) integrins VLA-5 and VLA-6. Cell. Immunol.
163:178.
- 20
76. Gresham, H.D., Graham, I.L., Anderson, D.C., and
Brown, E.J. (1991). Leukocyte adhesion-deficient
neutrophils fail to amplify phagocytic function in
response to stimulation. Evidence for
CD11b/CD18-dependent and -independent mechanisms of
phagocytosis. J. Clin. Invest. 88:588.

SEQUENCE LISTING

(1) GENERAL INFORMATION:

- (i) APPLICANT: The Trustees Of Columbia University In The City
Of New York
- (ii) TITLE OF INVENTION: A METHOD OF PREVENTING AND TREATING
BACTERIAL INFECTION OF SUTURES AND
PROSTHETIC DEVICES, AND PROMOTING
INGRESS OF LEUKOCYTES INTO TUMOR FOCI
- (iii) NUMBER OF SEQUENCES: 2
- (iv) CORRESPONDENCE ADDRESS:
 - (A) ADDRESSEE: Cooper & Dunham LLP
 - (B) STREET: 1185 Avenue of the Americas
 - (C) CITY: New York
 - (D) STATE: New York
 - (E) COUNTRY: U.S.A.
 - (F) ZIP: 10036
- (v) COMPUTER READABLE FORM:
 - (A) MEDIUM TYPE: Floppy disk
 - (B) COMPUTER: IBM PC compatible
 - (C) OPERATING SYSTEM: PC-DOS/MS-DOS
 - (D) SOFTWARE: PatentIn Release #1.0, Version #1.30
- (vi) CURRENT APPLICATION DATA:
 - (A) APPLICATION NUMBER:
 - (B) FILING DATE:
 - (C) CLASSIFICATION:
- (viii) ATTORNEY/AGENT INFORMATION:
 - (A) NAME: White, John P
 - (B) REGISTRATION NUMBER: 28,678
 - (C) REFERENCE/DOCKET NUMBER: 48940-A-PCT/JPW/JKM
- (ix) TELECOMMUNICATION INFORMATION:
 - (A) TELEPHONE: 212-278-0400
 - (B) TELEFAX: 212-391-0525

(2) INFORMATION FOR SEQ ID NO:1:

- (i) SEQUENCE CHARACTERISTICS:
 - (A) LENGTH: 6 amino acids
 - (B) TYPE: amino acid
 - (C) STRANDEDNESS: single
 - (D) TOPOLOGY: linear
- (ii) MOLECULE TYPE: peptide
- (iii) HYPOTHETICAL: NO
- (iv) ANTI-SENSE: NO
- (xi) SEQUENCE DESCRIPTION: SEQ ID NO:1:

Gly	Arg	Gly	Asp	Ser	Pro
1				5	

0917849-103293

Gly Arg Gly Asp Ser Pro
1 5

(2) INFORMATION FOR SEQ ID NO:2:

- (1) SEQUENCE CHARACTERISTICS:
 - (A) LENGTH: 6 amino acids
 - (B) TYPE: amino acid
 - (C) STRANDEDNESS: single
 - (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: peptide

(iii) HYPOTHETICAL: NO

(iv) ANTI-SENSE: NO

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:2:

Gly Arg Gly Glu Ser Pro
1 5

bioRxiv preprint doi: <https://doi.org/10.1101/000000>; this version posted March 1, 2014. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted bioRxiv a license to display the preprint in perpetuity. It is made available under aCC-BY-NC-ND 4.0 International license.

What is claimed is:

1. A method of treating an infection caused by bacterial cells located on a surface of a foreign body over and around which fibrin has been deposited, the foreign body being present in a subject, which comprises administering to the subject an agent capable of inhibiting signalling mediated by a β_2 integrin cell surface receptor of leukocyte cells in an amount effective to enhance the migration of leukocyte cells into or through the fibrin so as to permit the leukocyte cells to reach and kill the bacterial cells and thereby treat the infection.
2. The method of claim 1, wherein the foreign body is a prosthetic device.
3. The method of claim 1, wherein the foreign body is a catheter.
4. The method of claim 1, wherein the foreign body is a suture.
5. The method of claim 1, wherein the subject is a mammal.
6. The method of claim 5, wherein the mammal is a human.
7. The method of claim 1, wherein the leukocyte cells are polymorphonuclear leukocyte cells.
8. The method of claim 7, wherein the polymorphonuclear leukocyte cells are neutrophils.
9. The method of claim 7, wherein the polymorphonuclear

0917843 103333
"E482160"

leukocyte cells are basophils.

10. The method of claim ~~7~~, wherein the polymorphonuclear leukocyte cells are eosinophils.

5

11. The method of claim 1, wherein the leukocyte cells are monocytes.

10

12. The method of claim 1, wherein the leukocyte cells are macrophages.

13. The method of claim 1, wherein the agent is a peptide.

15

14. The method of claim 13, wherein the peptide contains a β_2 integrin-binding domain.

20

15. The method of claim 14, wherein the peptide comprises GRGDSP.

25

16. The method of claim 1, wherein the agent is an antibody or a fragment thereof that specifically binds to the β_2 integrin cell surface receptor of leukocyte cells.

30

17. A method of preventing a chronic infection from occurring due to the presence of bacterial cells on a surface of a foreign body in a subject, which comprises coating the foreign body before placing it in the subject with a fibrinolytic agent capable of preventing the accumulation of fibrin on the surface of the foreign body so as to permit leukocyte cells to reach and kill any bacterial cells present on the surface of the foreign body and thereby prevent the chronic infection.

35

18. The method of claim 17, wherein the foreign body is

05477843 102293

a prosthetic device.

- 5
19. The method of claim 17, wherein the foreign body is a catheter. —
20. The method of claim 17, wherein the foreign body is a suture. —
- 10
21. The method of claim 17, wherein the subject is a mammal. —
22. The method of claim 21, wherein the mammal is a human. —
- 15
23. The method of claim 17, wherein the fibrinolytic agent is a plasminogen activator.
24. The method of claim 23, wherein the plasminogen activator is urokinase. —
- 20
25. The method of claim 23, wherein the plasminogen activator is streptokinase.
26. The method of claim 23, wherein the plasminogen activator is tissue plasminogen activator.
- 25
27. A method of treating a malignant tumor comprising of malignant tumor cells over and around which tenascin has been deposited, the malignant tumor being present in a subject, which comprises administering to the subject an agent capable of inhibiting — signalling mediated by a β_1 integrin cell surface receptor of leukocyte cells in an amount effective to enhance the migration of leukocyte cells through the tenascin so as to permit the leukocyte cells to reach and kill the malignant tumor cells and thereby treat the malignant tumor.
- 30
- 35

20250704 14:48:46

28. The method of claim 27, wherein the subject is a mammal.
- 5 29. The method of claim 28, wherein the mammal is a human.
30. The method of claim 27, wherein the leukocyte cells are polymorphonuclear leukocyte cells.
- 10 31. The method of claim 30, wherein the polymorphonuclear leukocyte cells are neutrophils.
32. The method of claim 30, wherein the polymorphonuclear leukocyte cells are basophils.
- 15 33. The method of claim 30, wherein the polymorphonuclear leukocyte cells are eosinophils.
- 20 34. The method of claim 27, wherein the leukocyte cells are monocytes.
35. The method of claim 27, wherein the leukocyte cells are macrophages.
- 25 36. The method of claim 27, wherein the leukocyte cells are lymphocyte cells.
37. The method of claim 36, wherein the lymphocyte cells are NK cells.
- 30 38. The method of claim 36, wherein the lymphocyte cells are Killer cells.
- 35 39. The method of claim 27, wherein the agent is a peptide.

362201" 442/60

40. The method of claim 39, wherein the peptide contains a β_2 integrin-binding domain.
- 5 41. The method of claim 40, wherein the peptide comprises GRGDSP.
42. The method of claim 27, wherein the agent is an antibody or a fragment thereof that specifically binds to the β_2 integrin cell surface receptor of leukocyte cells.
- 10 43. A method of treating a chronic inflammation in a subject caused by an increase in the number of leukocyte cells present at the site of the chronic inflammation which comprises administering to the subject an agent capable of stimulating signalling mediated by a β_2 integrin cell surface receptor of leukocyte cells in an amount effective to inhibit the migration of leukocyte cells toward the site of the chronic inflammation so as to reduce the number of leukocyte cells present at the site and thereby treat the chronic inflammation.
- 15 44. The method of claim 43, wherein the subject is a mammal.
- 20 45. The method of claim 44, wherein the mammal is a human.
- 25 46. The method of claim 43, wherein the leukocyte cells are polymorphonuclear leukocyte cells.
- 30 47. The method of claim 46, wherein the polymorphonuclear leukocyte cells are neutrophils.
- 35 48. The method of claim 46, wherein the polymorphonuclear leukocyte cells are basophils.

2025 RELEASE UNDER E.O. 14176

A METHOD OF PREVENTING AND TREATING BACTERIAL INFECTION
OF SUTURES AND PROSTHETIC DEVICES, AND PROMOTING
INGRESS OF LEUKOCYTES INTO TUMOR FOCI

5 Abstract of the Disclosure

10 An agent capable of inhibiting signalling mediated by a
15 β_1 integrin cell surface receptor of leukocyte cells will
treat a bacterial infection associated with a surface of
a foreign body over and around which fibrin has been
deposited, or a malignant tumor over and around which
tenascin has been deposited. In addition, coating a
foreign body with a fibrinolytic agent will prevent
chronic bacterial infection associated with the surface
of the foreign body. Furthermore, an agent capable of
stimulating signalling mediated by a β_1 integrin cell
surface receptor of leukocyte cells will treat chronic
inflammation.

09177347-102298

FIG. 1B




FIG. 1A




FIG. 2A




FIG. 2B




FIG. 3B




FIG. 3A




FIG. 4




FIG. 5B

4 h




FIG. 5D

FIG. 5A

1 h




FIG. 5C

FIG. 5E

1h




FIG. 5F

4h



FIG. 6




FIG. 7A




FIG. 7B





FIG. 8







FIG. 10A




FIG. 10B




FIG. 11A




FIG. 11B




FIG. 12




FIG. 13A




FIG. 13B




FIG. 14




FIG. 15




FIG. 16




FIG. 17A





FIG. 17B



LaCanas Tucker
c/o Cooper & Dunham LLP
1185 Avenue of the Americas
New York, New York 10036
(212) 278-0400